Podcasts about clinical characteristics

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases. In this new episode of the ASO Episode Series of SurgOnc Today® (previously Speaking of SurgOnc), Dr. Rick Greene discusses with Dr. Michael Offin the clinicopathologic characteristics and outcomes of a large prospective cohort of well-differentiated papillary peritoneal mesothelial tumors, as reported in their article, "Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors."

Emile Daoud, MD, Associate Editor of JACC: Clinical Electrophysiology discusses a recently published original research paper on Clinical Characteristics and Outcomes in Patients with Atrial Fibrillation and Pathogenic TTN Variants.

This week we're traveling back to 1940s Venice with A Haunting in Venice! Join us as we learn about mad honey, When the Lights Go On Again, the liberation of Bergen-Belsen, Meet Me In St. Louis, and more! Sources: Gunduz, Abdülkadir;Şimşek, Perihan;Ayaz, Faik Ahmet, "Worldwide Distribution and Clinical Characteristics of Mad Honey Poisoning Cases," Central European Journal of Public Health (March 2023) Niko Vorobyov, "What It's Like Tripping on Mad Honey, the Hallucinogen That is (Maybe) an Aphrodisiac," Salon, 2022, available at https://www.salon.com/2022/04/10/what-its-like-tripping-on-mad-honey-the-hallucinogen-that-maybe-is-an-aphrodisiac/ Mad Honey, Atlas Obscura, available at https://www.atlasobscura.com/foods/mad-honey-red-hallucinogen Imperial War Museum, Collection of Accounts: https://www.iwm.org.uk/history/the-liberation-of-bergen-belsen https://en.wikipedia.org/wiki/When_the_Lights_Go_On_Again The Waterbury Democrat. [volume] (Waterbury, Conn.), 10 Nov. 1944. Chronicling America: Historic American Newspapers. Lib. of Congress. https://chroniclingamerica.loc.gov/lccn/sn82014085/1944-11-10/ed-1/seq-12/  The Michigan chronicle. [volume] (Detroit, Mich.), 29 May 1943. Chronicling America: Historic American Newspapers. Lib. of Congress. https://chroniclingamerica.loc.gov/lccn/sn83045324/1943-05-29/ed-1/seq-12/  https://genius.com/Vera-lynn-when-the-lights-go-on-again-lyrics  "https://catalog.archives.gov/id/24508 MOVIES AT WAR Other title:Film Bulletin, no. 107 (1943)" https://en.wikipedia.org/wiki/Meet_Me_in_St._Louis Matt Zoller Seitz, "A Haunting in Venice," https://www.rogerebert.com/reviews/a-haunting-in-venice-movie-review-2023  Wiki: https://en.wikipedia.org/wiki/A_Haunting_in_Venice  Justin Chang, "The big twist in 'A Haunting in Venice'? It's actually a great film," NPR, https://www.npr.org/2023/09/22/1201010896/a-haunting-in-venice-review-agatha-christie-hercule-poirot  https://variety.com/2023/film/news/haunting-in-venice-producer-more-poirot-movies-tina-fey-1235726819/ Todd Gilchrist, "'A Haunting in Venice' Review: Kenneth Branagh Brings a Supernatural Dimension to His Hercule Poirot Series," Variety (Sep. 9, 2023). https://variety.com/2023/film/reviews/a-haunting-in-venice-review-kenneth-branagh-1235717211/ 

Ślachetne zdrowie,Nikt się nie dowie,Jako smakujesz,Aż się zepsujesz.No więc ja nie chcę być tym smakoszem, co to się delektuje musztardą po obiedzie.Na warsztat bierzemy kolejny wymiar dobrostanu według narzędzia Wellbeing Score by @multilife czyli zdrowie fizyczne. I zapytacie “ale co Ty nam dziunia opowiesz o zdrowiu fizycznym, jak Ty nawet lekarzem nie jesteś?”. Doktorem niby tak, ale takim, ale bez strzykawy i stetoskopu, he he. W kompetencje lekarskie mieszać się nie będę, ALE: O lęku o zdrowie i tym, co nas przed dbaniem o nie powstrzymuje, już do powiedzenia co nieco mam. Na przykład amerykański National Institute of Mental Health podaje: Ryzyko wystąpienia depresji jest wyższe u osób cierpiących na choroby przewlekłe. I w drugą stronę: Wyzwania związane z wykonywaniem zadań korzystnych dla zdrowia, takich jak prawidłowe odżywianie i ćwiczenia, ze względu na objawy takie jak apatia w depresji także są utrudnione. Naczynia połączone, co nie? Więc wrzućmy na poznawczy ruszt unikanie, katastrofizację, objawy somatyczne, badania profilaktyczne, lęk przed krwią, aktywność fizyczną i zobaczmy, co nam z tego wyniknie.Zapraszam do kolejnego odcinka letniego wyzwania powered by @multilifeMontaż: Eugeniusz KarlovLiteratura:American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 2013, 5th edition, American Psychiatric AssociationScarella, Timothy M. MD; Boland, Robert J. MD; Barsky, Arthur J. MD. Illness Anxiety Disorder: Psychopathology, Epidemiology, Clinical Characteristics, and Treatment. Psychosomatic Medicine 81(5):p 398-407, June 2019.

Dive into the fascinating world of immunoglobulin A nephropathy (IgAN), the most common form of primary glomerulonephritis worldwide. Credit available for this activity expires: 7/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001351?ecd=bdc_podcast_libsyn_mscpedu

Victoria Werth, MD interviewed by Flavia Fedeles, MD, FAAD

   Join us on War Docs as we welcome Army Physician MAJ Mary Ford, an infectious disease specialist and lead author of the acclaimed Military Medicine Journal's article of the year: Clinical Characteristics and Resistance Patterns of Pseudomonas aeruginosa Isolated From Combat Casualties https://pubmed.ncbi.nlm.nih.gov/34196358/    Listen in as MAJ Ford shares the impactful findings of her team's research on Pseudomonas aeruginosa in combat casualties, a topic of paramount importance to military health. Her personal journey into the infectious disease field, spurred by early curiosities and familial influences, and the progression of her military career make for a captivating story of dedication and passion.       In this engaging conversation, we also tackle the critical subject of infection prevention and antimicrobial stewardship in the face of combat trauma. Hear about the vital role of simple measures, like hand hygiene, in combating infections, especially those caused by the antibiotic-resistant Pseudomonas aeruginosa. Discover how MAJ Ford's team utilized the Trauma Infectious Disease Outcomes Study to uncover that approximately 6% of combat trauma patients developed Pseudomonas infections. The implications of these findings are vast, offering significant advancements for clinical outcomes and infection control in military medical settings. Tune in for a deep understanding of how such research continues to shape practices and policies within the Department of Defense.   Chapters: (00:02) Infectious Disease in the Military (07:12) Combat Trauma Infections and Pseudomonas   Chapter Summaries: (00:02) Infectious Disease in the Military  MAJ Mary Ford's research on Pseudomonas aeruginosa in combat casualties and its impact on military health, her personal journey into infectious disease, and the enduring need for ongoing research in the Department of Defense.   (07:12) Combat Trauma Infections and Pseudomonas   Infection prevention and antimicrobial stewardship are crucial in controlling Pseudomonas infections in combat trauma patients.   Take Home Messages: In the context of military medicine, the issue of infections following combat trauma is a significant concern, with Pseudomonas aeruginosa identified as a noteworthy pathogen due to its prevalence in prolonged hospital stays and its intrinsic antibiotic resistance mechanisms. Infection prevention and antimicrobial stewardship are critical components in the management of combat trauma infections. Basic practices such as hand hygiene play a pivotal role in controlling the spread of infections and can have substantial impacts on patient outcomes. Research conducted through the Trauma Infectious Disease Outcomes Study (T-DOS) has revealed that about 6% of combat trauma patients develop Pseudomonas infections, which underscores the importance of understanding and addressing these infections to improve clinical practices and infection control protocols. Combat trauma patients with Pseudomonas infections often experience lengthy hospital stays and intensive care unit admissions, highlighting the need for robust infection prevention strategies in military healthcare settings to reduce the burden of these nosocomial infections. The fight against infections like Pseudomonas aeruginosa in military medicine is an ongoing challenge that requires continuous research and evidence-based practices to ensure the health and readiness of military personnel. Basic infection control measures remain foundational in mitigating infectious threats.   Episode Keywords:  Military Medicine, Infectious Disease, Pseudomonas aeruginosa, Combat Trauma, Antimicrobial Stewardship, Research, Clinical Practices, Infection Control, Military Health, Nosocomial Pathogen, Antibiotic Resistance, Retrospective Analysis, Prospectively Collected Data, Trauma Infectious Disease Outcomes Study, Clinical Outcomes, Infection Prevention, Military Medical Environments Hashtags: #wardocs #military #medicine #podcast #MilMed #MedEd #MilitaryMedicine, #PseudomonasAeruginosa, #CombatInfections, #InfectiousDiseases, #AntimicrobialStewardship, #WarDocsPodcast, #MilitaryHealthcare, #TraumaInfections, #InfectionPrevention, #ClinicalResearch   Honoring the Legacy and Preserving the History of Military Medicine   The WarDocs Mission is to honor the legacy, preserve the oral history, and showcase career opportunities, unique expeditionary experiences, and achievements of Military Medicine. We foster patriotism and pride in Who we are, What we do, and, most importantly, How we serve Our Patients, the DoD, and Our Nation.   Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/our-guests Subscribe and Like our Videos on our YouTube Channel: https://www.youtube.com/@wardocspodcast   Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm   WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible and go to honoring and preserving the history, experiences, successes, and lessons learned in Military Medicine. A tax receipt will be sent to you.   WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield, demonstrating dedication to the medical care of fellow comrades in arms.     Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast YouTube Channel: https://www.youtube.com/@wardocspodcast  

Dr. Justin Abbatemarco and Dr. Ellen Iacobaeus discuss patient characteristics, disease-modifying therapy, and disability progression in patients with late-onset MS and adult-onset MS.   Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000208051

Dr. Justin Abbatemarco talks with Dr. Ellen Iacobaeus about patient characteristics, disease-modifying therapy, and disability progression in Swedish patients with late-onset MS and adult-onset MS over 2 decades. Read the related article in Neurology.   Disclosures can be found at Neurology.org.  

Although it's often thought of as an adolescent affliction, acne can affect people well into adulthood.But some people seem to be immune to pimples. Why?Norman and Tegan investigate why some people are more prone to pimples than others, and what you might be able to do about it.Got a health question? Shoot us a line @ABCHealth on Instagram, or send a voice memo to thatrash@abc.net.au. We'd love to hear from you!Looking for COVID-19 updates? Don't panic, they've moved over to The Health ReportReferences:Racial Differences in Clinical Characteristics, Perceptions and Behaviors, and Psychosocial Impact of Adult Female AcneThe association between stress and acne among female medical students in Jeddah, Saudi ArabiaSeasonal aggravation of acne in summers and the effect of temperature and humidity in a study in a tropical settingEnjoyment of watching pimple popping videos: An fMRI investigation

In this episode, PeDRA Pub Club host, Donglin Zhang and guest panelists, Christina Boull, MD, Diana Reusch, MD, and Cristina Foschi, MD discuss a recent PeDRA publication, Clinical Characteristics of Infantile Hemangiomas with Aggressive, Persistent, and Destructive Ulceration. This collaborative, multi-site, retrospective study was originally published on October 16, 2023, in Pediatric Dermatology and was supported by a 2016 PeDRA Team Research Grant and a 2021 PeDRA Study Support Grant. Whether you're a longtime pediatric dermatologist, currently in training, or a patient or advocate who wants to learn more about the latest research in pediatric dermatology, this podcast is for you. In an approachable roundtable discussion, listeners will gain insight into publications relating to pediatric dermatology and learn what the research means for patients and providers.

Syphilis is often known as the “the great masquerader” because it can mimic symptoms and look like a wide array of other diseases. Dr. Edmund Tsui interviews Dr. Michael Huvard to get to the bottom of how acute syphilitic posterior placoid chorioretinopathy presents itself in eyes and the outcomes for these patients, from his Ophthalmology article “Clinical Characteristics and Visual Outcomes of Acute Syphilitic Posterior Placoid Chorioretinopathy” Clinical Characteristics and Visual Outcomes of Acute Syphilitic Posterior Placoid Chorioretinopathy. Mirzania, Delaram et al. Ophthalmology Retina, Volume 7, Issue 12, 1080 - 1086 Sign up for the next Ophthalmology Journal Virtual Club on March 6, 2024, at https://store.aao.org/ophthalmology-virtual-journal-club.html

CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-pd-l1-exploring-clinical-characteristics-of-ggej-cancers-in-relation-to-biomarker-positivity/18023/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Commentary by Dr Raul Santos

This episode is hosted by Julie Yang, MD, a gastroenterologist at the Icann School of Medicine at Mount Sinai, New York, USA and features Toni T. Seppälä, M.D., PhD, a GI surgeon and Professor of Cancer Research at Tampere University, Helsinki, Finland. They discuss the results from a retrospective analysis published this year, “Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry,"  which can be found here. Read our blog post "Insights gained from the largest cohort of patients with pancreaticobiliary cancer and Lynch Syndrome" here

An elderly client has severe back and hip pain as she recovers from her second bout with COVID. Her doctor gave her a steroid shot, but her MT wonders if the pain is a post-viral form of myalgia. Join us in this episode of “I Have a Client Who . . .” as we look at some research about post-COVID musculoskeletal pain and the many mechanisms involved (and host Ruth Werner throws a short tantrum about a narrowly focused study that misses some important factors). Sponsors:     Books of Discovery: www.booksofdiscovery.com     Host Bio:                    Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.                                      Recent Articles by Ruth:          “Working with Invisible Pain,” Massage & Bodywork magazine, November/December 2022, page 36, http://www.massageandbodyworkdigital.com/i/1481961-november-december-2022/38   “Unpacking the Long Haul,” Massage & Bodywork magazine, January/February 2022, page 35, www.massageandbodyworkdigital.com/i/1439667-january-february-2022/36. “Chemotherapy-Induced Peripheral Neuropathy and Massage Therapy,” Massage & Bodywork magazine, September/October 2021, page 33, http://www.massageandbodyworkdigital.com/i/1402696-september-october-2021/34.           “Pharmacology Basics for Massage Therapists,” Massage & Bodywork magazine, July/August 2021, page 32, www.massageandbodyworkdigital.com/i/1384577-july-august-2021/34.           Resources:    Pocket Pathology: https://www.abmp.com/abmp-pocket-pathology-app   Alnamlah, O.S. and Almarwani, M.M. (2023) ‘Musculoskeletal pain post-COVID-19 in patients undergoing physical therapy in Saudi Arabia: a cross-sectional study', BMC Musculoskeletal Disorders, 24, p. 507. Available at: https://doi.org/10.1186/s12891-023-06647-9.   Cevei, M. et al. (2022) ‘Rehabilitation of Post-COVID-19 Musculoskeletal Sequelae in Geriatric Patients: A Case Series Study', International Journal of Environmental Research and Public Health, 19(22), p. 15350. Available at: https://doi.org/10.3390/ijerph192215350.   Khoja, O. et al. (2022) ‘Clinical Characteristics and Mechanisms of Musculoskeletal Pain in Long COVID', Journal of Pain Research, 15, pp. 1729–1748. Available at: https://doi.org/10.2147/JPR.S365026.   Tiwari, V. and Bergman, M.J. (2023) ‘Viral Arthritis', in StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK531507/ (Accessed: 18 September 2023).     My articles on COVID and massage:   Massage & Bodywork - JANUARY | FEBRUARY 2022 (no date). Available at: https://www.massageandbodyworkdigital.com/i/1439667-january-february-2022/36? (Accessed: 20 September 2023).   Massage & Bodywork - SEPTEMBER | OCTOBER 2020 (no date). Available at: https://www.massageandbodyworkdigital.com/i/1276187-september-october-2020/46? (Accessed: 20 September 2023).    

Today, you'll learn about Locked-in Syndrome, the connection between social anxiety and nostalgia, and how continental shift is knocking GPS out of whack. Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/locked-in-syndrome-anxiety-nostalgia-continental-shiftLocked-in Syndrome“Demographic, Medical, and Clinical Characteristics of a Population Based Sample of Patients With Long-lastic Locked-in Syndrome.” by Helle Walseth Nilsen, et al. 2023.https://n.neurology.org/content/early/2023/07/13/WNL.0000000000207577“Locked-In Syndrome.” by Joe M Das, et al. 2022.https://www.ncbi.nlm.nih.gov/books/NBK559026/“Voicing Inner Thoughts Matters Kate Allatt TEDxSheffieldHallamUniversity.” YouTube. 2015.https://youtu.be/SptlyNYjtIUAnxiety & Nostalgia “Nostalgia Counteracts Social Anxiety and Enhances Interpersonal Competence.” by Yuwan Dai, et al. 2023https://journals.sagepub.com/doi/abs/10.1177/19485506231187680?journalCode=sppa“Social anxiety in young people: A prevalence study in seven countries.” by Philip Jefferies and Michael Ungar. 2020.https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239133“Social Anxiety Disorder: More Than Just Shyness.” NIH. n.d.https://www.nimh.nih.gov/health/publications/social-anxiety-disorder-more-than-just-shynessContinental Shift “Australia on the move: how GPS keeps up with a continent in constant motion.” by Chris Rizos & Donald Grant. 2017.https://theconversation.com/australia-on-the-move-how-gps-keeps-up-with-a-continent-in-constant-motion-71883“Australia Is Drifting So Fast GPS Can't Keep Up.” by Brian Clark Howard. 2016.https://www.nationalgeographic.com/science/article/australia-moves-gps-coordinates-adjusted-continental-drift?loggedin=true&rnd=1690986363340“GPS Accuracy.” GPS.gov. 2022.https://www.gps.gov/systems/gps/performance/accuracy/Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.

This is the first of a special podcast series on obstetric critical care.  I am joined on this series by Dr. Elizabeth Garchar, MD, FACOG.  She is an OB/GYN and Maternal Fetal Medicine (MFM) specialist who has a special interest in obstetric critical care.  She is also unique in that she flies regularly with our critical care transport teams and acts as one of our Assistant Medical Directors for the flight program.  So, Dr. Garchar has unique insight into managing this population in transport. This podcast focuses on severe postpartum hemorrhage.  We discuss the epidemiology and risk factors as well as the nuances of diagnosis, specifically how blood loss is actually quantified in this setting.  We also go through the importance of point-of-care ultrasound to help identify and manage the causes of postpartum hemorrhage.  Then, we transition to the discussion of management, focusing on the medical management of uterine atony, and also go over advanced interventions such as uterine packing, balloon tamponade devices, and REBOA.  Finally, Dr. Garchar discusses the indication and procedure for emergent hysterectomy as well as the post-procedure management critical care transport crews may have to perform.   References   Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. Oct 2017;130(4):e168-e186. doi:10.1097/aog.0000000000002351 Abdel-Aleem H, Singata M, Abdel-Aleem M, Mshweshwe N, Williams X, Hofmeyr GJ. Uterine massage to reduce postpartum hemorrhage after vaginal delivery. Int J Gynaecol Obstet. Oct 2010;111(1):32-6. doi:10.1016/j.ijgo.2010.04.036 Abul A, Al-Naseem A, Althuwaini A, Al-Muhanna A, Clement NS. Safety and efficacy of intrauterine balloon tamponade vs uterine gauze packing in managing postpartum hemorrhage: A systematic review and meta-analysis. AJOG Glob Rep. Feb 2023;3(1):100135. doi:10.1016/j.xagr.2022.100135 Aibar L, Aguilar MT, Puertas A, Valverde M. Bakri balloon for the management of postpartum hemorrhage. Acta Obstet Gynecol Scand. Apr 2013;92(4):465-7. doi:10.1111/j.1600-0412.2012.01497.x Bagga R, Jain V, Kalra J, Chopra S, Gopalan S. Uterovaginal packing with rolled gauze in postpartum hemorrhage. MedGenMed. Feb 13 2004;6(1):50. Borger van der Burg BLS, van Dongen T, Morrison JJ, et al. A systematic review and meta-analysis of the use of resuscitative endovascular balloon occlusion of the aorta in the management of major exsanguination. Eur J Trauma Emerg Surg. Aug 2018;44(4):535-550. doi:10.1007/s00068-018-0959-y Castellini G, Gianola S, Biffi A, et al. Resuscitative endovascular balloon occlusion of the aorta (REBOA) in patients with major trauma and uncontrolled haemorrhagic shock: a systematic review with meta-analysis. World J Emerg Surg. Aug 12 2021;16(1):41. doi:10.1186/s13017-021-00386-9 Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. May 27 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4 Cunningham FG, Nelson DB. Disseminated Intravascular Coagulation Syndromes in Obstetrics. Obstet Gynecol. Nov 2015;126(5):999-1011. doi:10.1097/AOG.0000000000001110 D'Alton M, Rood K, Simhan H, Goffman D. Profile of the Jada(R) System: the vacuum-induced hemorrhage control device for treating abnormal postpartum uterine bleeding and postpartum hemorrhage. Expert Rev Med Devices. Sep 2021;18(9):849-853. doi:10.1080/17434440.2021.1962288 Dildy GA, 3rd. Postpartum hemorrhage: new management options. Clin Obstet Gynecol. Jun 2002;45(2):330-44. doi:10.1097/00003081-200206000-00005 Dueckelmann AM, Hinkson L, Nonnenmacher A, et al. Uterine packing with chitosan-covered gauze compared to balloon tamponade for managing postpartum hemorrhage. Eur J Obstet Gynecol Reprod Biol. Sep 2019;240:151-155. doi:10.1016/j.ejogrb.2019.06.003 Erez O. Disseminated intravascular coagulation in pregnancy: New insights. Thrombosis Update. 2022;6doi:10.1016/j.tru.2021.100083 Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. Oct 2015;213(4):452-63. doi:10.1016/j.ajog.2015.03.054 Erez O, Othman M, Rabinovich A, Leron E, Gotsch F, Thachil J. DIC in Pregnancy - Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments. J Blood Med. 2022;13:21-44. doi:10.2147/JBM.S273047 Feng S, Liao Z, Huang H. Effect of prophylactic placement of internal iliac artery balloon catheters on outcomes of women with placenta accreta: an impact study. Anaesthesia. Jul 2017;72(7):853-858. doi:10.1111/anae.13895 Higgins N, Patel SK, Toledo P. Postpartum hemorrhage revisited: new challenges and solutions. Curr Opin Anaesthesiol. Jun 2019;32(3):278-284. doi:10.1097/ACO.0000000000000717 Ji SM, Cho C, Choi G, et al. Successful management of uncontrolled postpartum hemorrhage due to morbidly adherent placenta with Resuscitative endovascular balloon occlusion of the aorta during emergency cesarean section - A case report. Anesth Pain Med (Seoul). Jul 31 2020;15(3):314-318. doi:10.17085/apm.19051 Kellie FJ, Wandabwa JN, Mousa HA, Weeks AD. Mechanical and surgical interventions for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. Jul 1 2020;7(7):CD013663. doi:10.1002/14651858.CD013663 Kogutt BK, Vaught AJ. Postpartum hemorrhage: Blood product management and massive transfusion. Semin Perinatol. Feb 2019;43(1):44-50. doi:10.1053/j.semperi.2018.11.008 Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. Apr 2009;145(1):24-33. doi:10.1111/j.1365-2141.2009.07600.x Liu C, Gao J, Liu J, et al. Predictors of Failed Intrauterine Balloon Tamponade in the Management of Severe Postpartum Hemorrhage. Front Med (Lausanne). 2021;8:656422. doi:10.3389/fmed.2021.656422 Lohano R, Haq G, Kazi S, Sheikh S. Intrauterine balloon tamponade for the control of postpartum haemorrhage. J Pak Med Assoc. Jan 2016;66(1):22-6. Maier RC. Control of postpartum hemorrhage with uterine packing. Am J Obstet Gynecol. Aug 1993;169(2 Pt 1):317-21; discussion 321-3. doi:10.1016/0002-9378(93)90082-t Makin J, Suarez-Rebling DI, Varma Shivkumar P, Tarimo V, Burke TF. Innovative Uses of Condom Uterine Balloon Tamponade for Postpartum Hemorrhage in India and Tanzania. Case Rep Obstet Gynecol. 2018;2018:4952048. doi:10.1155/2018/4952048 Natarajan A, Alaska Pendleton A, Nelson BD, et al. Provider experiences with improvised uterine balloon tamponade for the management of uncontrolled postpartum hemorrhage in Kenya. Int J Gynaecol Obstet. Nov 2016;135(2):210-213. doi:10.1016/j.ijgo.2016.05.006 Natarajan A, Kamara J, Ahn R, et al. Provider experience of uterine balloon tamponade for the management of postpartum hemorrhage in Sierra Leone. Int J Gynaecol Obstet. Jul 2016;134(1):83-6. doi:10.1016/j.ijgo.2015.10.026 Okoye HC, Nwagha TU, Ugwu AO, et al. Diagnosis and treatment of bbstetrics disseminated intravascular coagulation in resource limited settings. Afr Health Sci. Mar 2022;22(1):183-190. doi:10.4314/ahs.v22i1.24 Ordonez CA, Manzano-Nunez R, Parra MW, et al. Prophylactic use of resuscitative endovascular balloon occlusion of the aorta in women with abnormal placentation: A systematic review, meta-analysis, and case series. J Trauma Acute Care Surg. May 2018;84(5):809-818. doi:10.1097/TA.0000000000001821 Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clin Appl Thromb Hemost. Dec 2018;24(9_suppl):8S-28S. doi:10.1177/1076029618806424 Pingray V, Widmer M, Ciapponi A, et al. Effectiveness of uterine tamponade devices for refractory postpartum haemorrhage after vaginal birth: a systematic review. BJOG. Oct 2021;128(11):1732-1743. doi:10.1111/1471-0528.16819 Quandalle A, Ghesquiere L, Kyheng M, et al. Impact of intrauterine balloon tamponade on emergency peripartum hysterectomy following vaginal delivery. Eur J Obstet Gynecol Reprod Biol. Jan 2021;256:125-129. doi:10.1016/j.ejogrb.2020.10.064 Rattray DD, O'Connell CM, Baskett TF. Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009). J Obstet Gynaecol Can. Apr 2012;34(4):341-347. doi:10.1016/S1701-2163(16)35214-8 Revert M, Rozenberg P, Cottenet J, Quantin C. Intrauterine Balloon Tamponade for Severe Postpartum Hemorrhage. Obstet Gynecol. Jan 2018;131(1):143-149. doi:10.1097/AOG.0000000000002405 Sadek S, Lockey DJ, Lendrum RA, Perkins Z, Price J, Davies GE. Resuscitative endovascular balloon occlusion of the aorta (REBOA) in the pre-hospital setting: An additional resuscitation option for uncontrolled catastrophic haemorrhage. Resuscitation. Oct 2016;107:135-8. doi:10.1016/j.resuscitation.2016.06.029 Schmid BC, Rezniczek GA, Rolf N, Saade G, Gebauer G, Maul H. Uterine packing with chitosan-covered gauze for control of postpartum hemorrhage. Am J Obstet Gynecol. Sep 2013;209(3):225 e1-5. doi:10.1016/j.ajog.2013.05.055 Shimada K, Taniguchi H, Enomoto K, Umeda S, Abe T, Takeuchi I. Hospital transfer for patients with postpartum hemorrhage in Yokohama, Japan: a single-center descriptive study. Acute Med Surg. Jan-Dec 2021;8(1):e716. doi:10.1002/ams2.716 Simpson KR. Update on Evaluation, Prevention, and Management of Postpartum Hemorrhage. MCN Am J Matern Child Nurs. Mar/Apr 2018;43(2):120. doi:10.1097/NMC.0000000000000406 Singer KE, Morris MC, Blakeman C, et al. Can Resuscitative Endovascular Balloon Occlusion of the Aorta Fly? Assessing Aortic Balloon Performance for Aeromedical Evacuation. J Surg Res. Oct 2020;254:390-397. doi:10.1016/j.jss.2020.05.021 Snyder JA, Schuerer DJE, Bochicchio GV, Hoofnagle MH. When REBOA grows wings: Resuscitative endovascular balloon occlusion of the aorta to facilitate aeromedical transport. Trauma Case Rep. Apr 2022;38:100622. doi:10.1016/j.tcr.2022.100622 Soued M, Vivanti AJ, Smiljkovski D, et al. Efficacy of Intra-Uterine Tamponade Balloon in Post-Partum Hemorrhage after Cesarean Delivery: An Impact Study. J Clin Med. Dec 28 2020;10(1)doi:10.3390/jcm10010081 Stensaeth KH, Sovik E, Haig IN, Skomedal E, Jorgensen A. Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage. PLoS One. 2017;12(3):e0174520. doi:10.1371/journal.pone.0174520 Suarez S, Conde-Agudelo A, Borovac-Pinheiro A, et al. Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis. Am J Obstet Gynecol. Apr 2020;222(4):293 e1-293 e52. doi:10.1016/j.ajog.2019.11.1287 Theron GB, Mpumlwana V. A case series of post-partum haemorrhage managed using Ellavi uterine balloon tamponade in a rural regional hospital. S Afr Fam Pract (2004). May 11 2021;63(1):e1-e4. doi:10.4102/safp.v63i1.5266 Tran QK, Hollis G, Beher R, et al. Transport of Peripartum Patients for Medical Management: Predictors of Any Intervention During Transport. Cureus. Nov 2022;14(11):e31102. doi:10.7759/cureus.31102 Weir R, Lee J, Almroth S, Taylor J. Flying with a Safety Net: Use of REBOA to Enable Safe Transfer to a Level 1 Trauma Center. Journal of Endovascular Resuscitation and Trauma Management. 2022;5(3)doi:10.26676/jevtm.v5i3.214 Wu Q, Liu Z, Zhao X, et al. Outcome of Pregnancies After Balloon Occlusion of the Infrarenal Abdominal Aorta During Caesarean in 230 Patients With Placenta Praevia Accreta. Cardiovasc Intervent Radiol. Nov 2016;39(11):1573-1579. doi:10.1007/s00270-016-1418-y Zeng KW, Ovenell KJ, Alholm Z, Foley MR. Postpartum Hemorrhage Management and Blood Component Therapy. Obstet Gynecol Clin North Am. Sep 2022;49(3):397-421. doi:10.1016/j.ogc.2022.02.001  See omnystudio.com/listener for privacy information.

This month on Episode 47 of Discover CircRes, host Cynthia St. Hilaire highlights three original research articles featured in the March 31 issue of Circulation Research. We'll also provide an overview of the Compendium on Increased Risk of Cardiovascular Complications in Chronic Kidney Disease published in the April 14 issue. Finally, this episode features an interview with Dr Elizabeth Tarling and Dr Bethan Clifford from UCLA regarding their study, RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels.   Article highlights:   Shi, et al. LncRNAs Regulate SMC Phenotypic Transition   Chen, et al. Bilirubin Stabilizes Atherosclerotic Plaque   Subramaniam, et al. Mapping Non-Obvious cAMP Nanodomains by Proteomics   Compendium on Increased Risk of Cardiovascular Complications in Chronic Kidney Disease   Cindy St. Hilaire:              Hi, and welcome to Discover CircRes, the podcast of the American Heart Association's Journal, Circulation Research. I'm your host, Dr Cindy St. Hilaire, from the Vascular Medicine Institute at the University of Pittsburgh, and today I'm going to share three articles selected from our March 31st issue of Circulation Research and give you a quick summary of our April 14th Compendium. I'm also excited to speak with Dr Elizabeth Tarling and Dr Bethan Clifford from UCLA regarding their study, RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels.   So first the highlights. The first article we're going to discuss is Discovery of Transacting Long Noncoding RNAs that Regulates Smooth Muscle Cell Phenotype. This article's coming from Stanford University and the laboratory of Dr Thomas Quertermous. Smooth muscle cells are the major cell type contributing to atherosclerotic plaques. And in plaque pathogenesis, the cells can undergo a phenotypic transition whereby a contractile smooth muscle cell can trans differentiate into other cell types found within the plaque, such as macrophage-like cells, osteoblast-like cells and fibroblast-like cells. These transitions are regulated by a network of genetic and epigenetic mechanisms, and these mechanisms govern the risk of disease.   The involvement of long non-coding RNAs, or Lnc RNAs as they're called, has been increasingly identified in cardiovascular disease. However, smooth muscle cell Lnc RNAs have not been comprehensively characterized and the regulatory role in the smooth muscle cell state transition is not thoroughly understood. To address this gap, Shi and colleagues created a discovery pipeline and applied it to deeply strand-specific RNA sequencing from human coronary artery smooth muscle cells that were stressed with different disease related stimuli. Subsequently, the functional relevancy of a few novel Lnc RNAs was verified in vitro.   From this pipeline, they identified over 4,500 known and over 13,000 unknown or previously unknown Lnc RNAs in human coronary artery smooth muscle cells. The genomic location of these long noncoding RNAs was enriched near coronary artery disease related transcription factor and genetic loci. They were also found to be gene regulators of smooth muscle cell identity. Two novel Lnc RNAs, ZEB-interacting suppressor or ZIPPOR and TNS1-antisense or TNS1-AS2, were identified by the screen, and this group discovered that the coronary artery disease gene, ZEB2, which is a transcription factor in the TGF beta signaling pathway, is a target for these Lnc RNAs. These data suggest a critical role for long noncoding RNAs in smooth muscle cell phenotypic transition and in human atherosclerotic disease.   Cindy St. Hilaire:              The second article I want to share is titled Destabilization of Atherosclerotic Plaque by Bilirubin Deficiency. This article is coming from the Heart Research Institute and the corresponding author is Roland Stocker. The rupture of atherosclerotic plaque contributes significantly to cardiovascular disease. Plasma concentrations of bilirubin, a byproduct of heme catabolism, is inversely associated with risk of cardiovascular disease, but the link between bilirubin and atherosclerosis is unknown.   Chen et el addressed this gap by crossing a bilirubin knockout mice to a atherosclerosis prone APOe knockout mouse. Chen et el addressed this gap by crossing the bilirubin knockout mouse to the atherosclerosis-prone APOE knockout mouse, and used the tandem stenosis model of plaque instability to address this question. Compared with their litter mate controls, bilirubin-APOE double knockouts showed signs of increased systemic oxidative stress, endothelial dysfunction, as well as hyperlipidemia. And they had higher atherosclerotic plaque burden.   Hemeatabolism was increased in unstable plaques compared with stable plaques in both of these groups as well as in human coronary arteries. In mice, the bilirubin deletion selectively destabilized unstable plaques and this was characterized by positive arterial remodeling and increased cap thinning, intra plaque hemorrhage, infiltration of neutrophils and MPO activity. Subsequent proteomics analysis confirmed bilirubin deletion enhanced extracellular matrix degradation, recruitment and activation of neutrophils and associated oxidative stress in the unstable plaque. Thus, bilirubin deficiency generates a pro atherogenic phenotype and selectively enhances neutrophil-mediated inflammation and destabilization of unstable plaques, thereby providing a link between bilirubin and cardiovascular disease risk.   Cindy St. Hilaire:              The third article I want to share is titled Integrated Proteomics Unveils Regulation of Cardiac Monocyte Hypertrophic Growth by a Nuclear Cyclic AMP Nano Domain under the Control of PDE3A. This study is coming from the University of Oxford in the lab of Manuela Zaccolo. Cyclic AMP is a critically important secondary messenger downstream from a myriad of signaling receptors on the cell surface. Signaling by cyclic AMP is organized in multiple distinct subcellular nano domains, regulated by cyclic AMP hydrolyzing phosphodiesterases or PDEs.   The cardiac beta adrenergic signaling has served as the prototypical system to elucidate this very complex cyclic AMP compartmentalization. Although studies in cardiac monocytes have provided an understanding of the location and the properties of a handful of these subcellular domains, an overview of the cellular landscape of the cyclic AMP nano domains is missing.   To understand the nanodynamics, Subramanian et al combined an integrated phospho proteomics approach that took advantage of the unique role that individual phosphodiesterases play in the control of local cyclic AMP. They combined this with network analysis to identify previously unrecognized cyclic AMP nano domains associated with beta adrenergic stimulation. They found that indeed this integrated phospho proteomics approach could successfully pinpoint the location of these signaling domains and it provided crucial cues to determine the function of previously unknown cyclic AMP nano domains.   The group characterized one such cellular compartment in detail and they showed that the phosphodiesterase PDE3A2 isoform operates in a nuclear nano domain that involves SMAD4 and HDAC1. Inhibition of PDE3 resulted in an increased HDAC1 phosphorylation, which led to an inhibition of its deacetylase activity, and thus derepression of gene transcription and cardiac monocyte hypertrophic growth. These findings reveal a very unique mechanism that explains the negative long-term consequences observed in patients with heart failure treated with PDE3 inhibitors.   Cindy St. Hilaire:              The April 14th issue is our compendium on Increased Risk of Cardiovascular Complications in Chronic Kidney Disease. Dr Heidi Noels from the University of Aachen is our guest editor of the 11 articles in this issue. Chronic kidney disease is defined by kidney damage or a reduced kidney filtration function. Chronic kidney disease is a highly prevalent condition affecting over 13% of the population worldwide and its progressive nature has devastating effects on patient health. At the end stage of kidney disease, patients depend on dialysis or kidney transplantation for survival. However, less than 1% of CKD patients will reach this end stage of chronic kidney disease. Instead, most of them with moderate to advanced chronic kidney disease will prematurely die and most often they die from cardiovascular disease. And this highlights the extreme cardiovascular burden patients with CKD have.   The titles of the articles in this compendium are the Cardio Kidney Patient Epidemiology, Clinical Characteristics, and Therapy by Nicholas Marx, the Innate Immunity System in Patients with Cardiovascular and Kidney Disease by Carmine Zoccali et al. NETs Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney disease by Yvonne Doering et al. Accelerated Vascular Aging and Chronic Kidney Disease, The Potential for Novel Therapies by Peter Stenvinkel et al. Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients with Chronic Kidney Disease by Heidi Noels et al. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease by Claudia Goettsch et al. Fibrosis in Pathobiology of Heart and Kidney From Deep RNA Sequencing to Novel Molecular Targets by Raphael Kramann et al. Cardiac Metabolism and Heart Failure and Implications for Uremic Cardiomyopathy by P. Christian Schulze et al. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease by Michael Burnier et al. Role of the Microbiome in Gut, Heart, Kidney crosstalk by Griet Glorieux et al, and Use of Computation Ecosystems to Analyze the Kidney Heart Crosstalk by Joachim Jankowski et al.   These reviews were written by leading investigators in the field, and the editors of Circulation Research hope that this comprehensive undertaking stimulates further research into the path flow of physiological kidney-heart crosstalk, and on comorbidities and intra organ crosstalk in general.   Cindy St. Hilaire:              So for our interview portion of the episode I have with me Dr Elizabeth Tarling and Dr Bethan Clifford. And Dr Tarling is an associate professor in the Department of Medicine in cardiology at UCLA, and Dr Clifford is a postdoctoral fellow with the Tarling lab. And today we're going to be discussing their manuscript that's titled, RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels. So thank you both so much for joining me today.   Elizabeth Tarling:             Thank you for having us.   Bethan Clifford:               Yeah, thanks for having us. This is exciting.   Cindy St. Hilaire:              I guess first, Liz, how did you get into this line of research? I guess, before we get into that, I should disclose. Liz, we are friends and we've worked together in the ATVB Women's Leadership Committee. So full disclosure here, that being said, the editorial board votes on these articles, so it's not just me picking my friends. But it is great to have you here. So how did you enter this field, I guess, briefly?   Elizabeth Tarling:             Yeah, well briefly, I mean my training right from doing my PhD in the United Kingdom in the University of Nottingham has always been on lipid metabolism, lipoprotein biology with an interest in liver and cardiovascular disease. So broadly we've always been interested in this area and this line of research. And my postdoctoral research was on atherosclerosis and lipoprotein metabolism. And this project came about through a number of different unique avenues, but really because we were looking for regulators of LDL biology and plasma LDL cholesterol, that's sort of where the interest of the lab lies.   Cindy St. Hilaire:              Excellent. And Bethan, you came to UCLA from the UK. Was this a topic you were kind of dabbling in before or was it all new for you?   Bethan Clifford:               It was actually all completely new for me. So yeah, I did my PhD at the same university as Liz and when I started looking for postdocs, I was honestly pretty adamant that I wanted to stay clear away from lipids and lipid strategy. And then it wasn't until I started interviewing and meeting people and I spoke to Liz and she really sort of convinced me of the excitement and that the interest and all the possibilities of working with lipids and well now I won't go back, to be honest.   Cindy St. Hilaire:              And now here you are. Well-   Bethan Clifford:               Exactly.   Cindy St. Hilaire:              ... congrats on a wonderful study. So LDLR, so low density lipoprotein receptor, it's a major determinant of plasmid LDL cholesterol levels. And hopefully most of us know and appreciate that that is really a major contributor and a major risk for the development of atherosclerosis and coronary artery disease. And I think one thing people may not really appreciate, which your study kind of introduces and talks about nicely, is the role of the liver, right? And the role of receptor mediated endocytosis in regulating plasma cholesterol levels. And so before we kind of chat about the nitty-gritty of your study, could you just give us a brief summary of these key parts between plasma LDL, the LDL receptor and where it goes in your body?   Elizabeth Tarling:             Yeah. So the liver expresses 70% to 80% of the body's LDL receptor. So it's the major determinant of plasma lipoprotein plasma LDL cholesterol levels. And through groundbreaking work by Mike Brown and Joe Goldstein at the University of Texas, they really define this receptor mediated endocytosis by the liver and the LDL receptor by looking at patients with familial hypercholesterolemia. So those patients have mutations in the LDL receptor and they either express one functional copy or no functional copies of the LDL receptor and they have very, very large changes in plasma LDL cholesterol. And they have severe increases in cardiovascular disease risk and occurrence and diseases associated with elevated levels of cholesterol within the blood and within different tissues. And so that's sort of how the liver really controls plasma LDL cholesterol is through this receptor mediated endocytosis of the lipoprotein particle.   Cindy St. Hilaire:              There's several drugs now that can help regulate our cholesterol levels. So there's statins which block that rate limiting step of cholesterol biosynthesis, but there's this new generation of therapies, the PCSK9 inhibitors. And can you just give us a summary or a quick rundown of what are those key differences really? What is the key mechanism of action that these therapies are going after and is there room for more improvement?   Bethan Clifford:               Yeah, sure. So I mean I think you've touched on something that's really key about the LDR receptor is that it's regulated at so many different levels. So we have medications available that target the production of cholesterol and then as you mentioned this newer generation of things like PCSK9 inhibitors that sort of try and target LDL at the point of clearance from the plasma.   And in response to your question of is there room for more regulation, I would say that given the sort of continual rate of increased cholesterol in the general population and the huge risks associated with elevated cholesterol, there's always capacity for more to improve that and sort of generally improve the health of the population. And what we sort of found particularly exciting about RNF130 is that it's a distinct pathway from any of these regulatory mechanisms. So it doesn't regulate the level of transcription, it doesn't regulate PCSK9. Or in response to PCSK9, it's a completely independent pathway that could sort of improve or add to changes in cholesterol.   Cindy St. Hilaire:              So your study, it's focusing on the E3 ligase, RNF130. What is an E3 ligase, and why was this particular one of interest to you? How did you come across it?   Elizabeth Tarling:             is predTates Bethan joining the lab. This is, I think, again for the listeners and those people in training, I think it's really important to note this project has been going in the lab for a number of years and has really... Bethan was the one who came in and really took charge and helped us round it out. But it wasn't a quick find or a quick story. It had a lot of nuances to it. But we were interested in looking for new regulators of LDL cholesterol and actually through completely independent pathways we had found the RNF130 locus as being associated with LDL cholesterol in animals. And then it came out in a very specific genome-wide association study in the African American care study, the NHLBI care study. And so really what we started looking at, we didn't even know what it was.   Elizabeth Tarling:             So we asked ourselves, well what is this gene? What is this protein? And it's RNF, so that's ring finger containing protein 130 and ring stands for really interesting new gene. Somebody came up with the glorious name. But proteins that contain this ring domain are very characteristic and they are E3 ubiquitin ligases. And so they conjugate the addition of ubiquitin to a target protein and that signals for that protein to either be internalized and/or degraded through different decorative pathways within the cell. And so we didn't land on it because we were looking at E3 ligases, we really came at it from an LDL cholesterol perspective. And it was something that we hadn't worked on before and the study sort of blossomed from there.   Cindy St. Hilaire:              That's amazing and a beautiful, but also, I'm sure, heartbreaking story because these long projects are just... They're bears. So what does this RNF130 do to LDLR? What'd you guys find?   Bethan Clifford:               As Liz said, this is a long process, but one of the key factors of RNF130 is it's structurally characteristically looked like E3 ligase. So the first thing that Liz did and then I followed up with in the lab is to see is this E3 ligase ubiquitinating in vitro. And if it is going to ubiquitinate, what's it likely to regulate that might cause changes in plasma cholesterol that would explain these human genetic links that we saw published at the same time.   And so because the LDL cholesterol is predominantly regulated by the LDL receptor and the levels of it at the surface of the parasites in the liver, the first question we wanted to see is does RNF130 interact in any way with that pathway? And I'm giving you the brief view here of the LDL receptor. We obviously tested lots of different receptors. We tested lots of different endocytose receptors and lipid regulators, but the LDL receptor is the one that we saw could be ubiquitinated by RNF130 in vitro. And so then we wanted to sort of go on from there and establish, okay, if this E3 ubiquitin ligase, is it regulating LDL receptor? What does that mean in an animal context in terms of regulating LDL cholesterol?   Cindy St. Hilaire:              Yeah, and I guess we should also explain, ubiquitination, in terms of this receptor, and I guess related to Goldstein and Brown and receptor mediated endocytosis, like what does that actually mean for the liver cell and the cholesterol in the LDLR that is binding the receptor?   Bethan Clifford:               So yes, ubiquitination is a really common regulatory mechanism actually across all sorts of different cells, all sorts of different receptors and proteins. And basically what it does is it signals for degradation of a protein. So a ubiquitin molecule is conjugated to its target such as in our case the LDL receptor and that ubiquitin tells the cell that this protein is ready for proteasomal degradation. And that's just one of the many things ubiquitination can do. It can also signal for a trafficking event, it can signal for a protein to protein interaction, but it's most commonly associated with the proteasomal degradation.     Cindy St. Hilaire:              So in terms of... I guess I'm thinking in terms of PCSK9, right? So those drugs are stemming from observations in humans, right? There were humans with gain and loss of function mutations, which caused either more or less of this LDLR receptor internalization. How is this RNF130 pathway different from the PCSK9 activities?   Elizabeth Tarling:             Yeah, so PCSK9 is a secreted protein, so it's made by hepatocyte and actually other cells in the body and it's secreted and it binds to the LDL particle, LDL receptor complex, and signals for its internalization and degradation in the proteasome. So this is not ubiquitination event, this is a completely different trafficking event. And so the RNF130, actually what Bethan showed, is it directly ubiquitinates the LDL receptor itself, signaling for an internalization event and then ultimately degradation of the LDR receptor through a decorative pathway, which we also define in the study.   So these are two unique mechanisms and actually some key studies that we did in the paper were to modulate RNF130 in animals that do not have PCSK9. And so in that system where in the absence of PCSK9 you have a lot of LDR receptor in the liver that's internalizing cholesterol. What happens when you overexpress RNF130? Do you still regulate at the LDL receptor? And you absolutely do. And so that again suggests that they're two distinct mechanisms and two distinct pathways.   Cindy St. Hilaire:              That was one thing I really loved about your paper is every kind of figure or section, the question that would pop up in my head, even ones that didn't pop in my head were beautifully answered with some of these really nice animal models, which is never an easy thing, right? And so one of the things that you brought up was difficulty in making one of the animal models. And so I'm wondering if you could share a little bit for that challenge. I think one thing that we always tend to hide is just science is hard and a lot of what we do doesn't work. And I really think especially for the trainees and really everyone out there, if we kind of share these things more, it's better. So what was one of the most challenging things in this study? And I guess I'm thinking about that floxed animal.   Elizabeth Tarling:             Yeah, so I'll speak a bit about that and then I'll let Bethan address because she was really the one on the ground doing a lot of the struggles. But again, we actually weren't going to include this information in the paper. And upon discussion and actually prompted by the reviewers of the paper and some of the questions that they asked us, we realized, you know what? It's actually really important to show this and show that this happens and that there are ways around it.   And so the first story is before Bethan even arrived in the lab, we had purchased embryonic stem cells that were knockout first condition already. And so this is a knockout strategy in which the exon of interest is flanked with lots of P sites so that you can create a flox animal, but also so you can create a whole body knockout just by the insertion of this knockout first cassette.   Elizabeth Tarling:             And so we got those mice actually in the first year of Bethan joining the lab. We finally got the chimeric mice and we were able to stop reading those mice. And at the same time we tried to generate our flox animals so that we could move on to do tissue-specific studies. And Bethan can talk about the pain associated with this. But over two years of breeding, we never got the right genotypes from the different crosses that you need to do to generate the flox animal.   And it was actually in discussions with Bethan where we decided we need to go back. We need to go back to those ESLs that we purchased five years ago and we need to figure out if all of the elements that the quality control step had told us were in place are actually present. And so Bethan went back and sequenced the whole locus and the cassette to figure out what pieces were present and we found that one of the essential locks P sites that's required for every single cross from the initial animal was absent and therefore we could actually never make the mouse we wanted to make.   And so that's sort of just a lesson for people going down that route and making these tools that we need in the lab to answer these questions is that despite paying extra money and getting all of the sort of QCs that you can get before you receive the ESLs, we should have gone back and done our own housekeeping and sort of a long journey told us when we went back that we didn't have what we thought we had at the beginning. And that was a real sticking point as Bethan can-   Cindy St. Hilaire:              Yeah. And so you know you're not alone. My very first postdoc that I did, I went with a mouse that they had also bought and were guaranteed that it was a knockout and it was not. And it is a painful lesson, but it is critical to... You get over it.   So Bethan, maybe you can also tell us a little bit about what are the other kind of next things you tried? You pivoted and you pivoted beautifully because all the models you used I thought were quite elegant in terms of exactly asking the question you wanted to ask in the right cells. So can you maybe explain some of the in vivo models you used for this study?   Bethan Clifford:               Sure, there are definitely a lot. So I mean I think Liz sort of encapsulated the trouble we have with the knockout really succinctly, but actually I want to just take this moment to sort of shout out to another postdoc in the Tarling lab, Kelsey Jarrett, who was really instrumental in the pivoting to a different model. So for the knockouts when we sort of established we didn't have exactly what we thought we did and then to compound that we also weren't getting the DeLiAn ratios breeding this whole body knockout.   We wanted to sort of look at a more transient knockout model. And that's where Kelsey really stepped in and sort of led the way and she generated AAV-CRISPR for us to target RNF130 specifically in the liver. And that had the added beauty of, one, not requiring breeding to get over this hurdle of the knockout being somewhat detrimental to breeding. But it also allowed us to ask the question of what RNF130 is doing specifically in the liver where the liver regulates LDL receptor and LDL cholesterol.   And so that was one of the key models that really, really helped get this paper over the finish line. But we did a whole barrage of experiments, as you've seen. We wanted to make sure... One of the key facets of the Tarling lab is whenever you do anything, no matter what you show Liz, it will always be, "Okay, you showed it to me one way, now show it to me a different way." Can you get the same result coming at it from different ways? And if you can't, why is that? What is the regulation behind that? And so that's really what the paper is doing is asking the same question in as many ways as we can accurately and appropriately probe what RNF130 does to the LDR receptor.   So we tried gain of function studies without adenovirus overexpression. We tried transient knockdown with antisense oligonucleotides, and then we did, as I said, the AAV-CRISPR knockdown with the help of Kelsey and our whole body knockout. And then we also repeated some of these studies such as the adenovirus and the ASO in specific genetic backgrounds. So in the absence of PCSK9, can we still regulate the LDL receptor? And then we also, just to really confirm this, in the absence of the LDL receptor, do we see a difference? And the answer is no, because this effect was really dependent on that LDL receptor being present. So there was a big combination.   Cindy St. Hilaire:              It was really nice, really a beautiful step-wise progression of how to solidly answer this question. But a lot of, I think, almost all you did was in mice. And so what is the genetic evidence for relevancy in humans? Can you discuss a little bit about those databases that you then went to to investigate, is this relevant in humans?   Bethan Clifford:               I think Liz might be better off answering that question.   Elizabeth Tarling:             And I think this sort of pivots on what Bethan was saying. So when we had struggles in the lab, it was a team environment and a collaboration between people in the lab that allowed us to make that leap and make those next experiments possible to then really answer that question. And to be able to include the antisense oligonucleotides required a collaboration with industry. We were very lucky to have a longstanding collaboration with Ionis, who provided the antisense oligonucleotides.   And for the human genetics side of things, that also was a collaboration with Marcus Seldin, who was a former postdoc with Jake Lusis and is now our PI at UC Irvine. And what he helped us do is dive into those summary level databases and ask from that initial study in the NHLBI care population, do we see associations of RNF130 expression in humans with LDL cholesterol with cardiovascular outcomes. And so one database which I would recommend everybody use, it's publicly available, is the StarNet database. And it's in the paper and the website is there. And that allowed us to search for RNF130.   Elizabeth Tarling:             And what it does is it asks how RNF130 expression in different tissues is associated with cardiometabolic outcomes and actual in CAD cases and controls, so people with and without heart disease. And we found that expression of RNF130 in the liver was extremely strongly correlated with the occurrence of cardiovascular disease in people with CAD. So in cases versus controls. And then we were also able to find many other polymorphisms in the RNF130 locus that were associated with LDL cholesterol in multiple different studies.   And I think the other message from this paper is this, unlike PCSK9 and unlike LDR receptor itself, which are single gene mutations that cause cardiovascular disease, there are many sub genome-wide significant loci that contribute to this multifactorial disease, which is extremely complex. And I think RNF130 falls within that bracket that those sort of just on the borderline of being genome-wide significant still play significant biological roles in regulating these processes. And they don't come up as a single gene hit for a disease, but combinatorialy they are associated with increased risk of disease and they have a molecular mechanism that's associated with the disease. And so that's what Marcus helped us do in terms of the human genetics is really understand that and get down to that level of data.   Cindy St. Hilaire:              Yeah. Yeah, it really makes you want to go back and look at those. Everyone always focuses on that really high peak and those analyses, but what are all those other ones above the noise, right? So it's really important.   Elizabeth Tarling:             I think it's really hard to do that. I think that's one where people... Again, it comes down to team science and the group of people that we brought together allowed us to ask that molecular question about how that signal was associated with the phenotype. I think by ourselves we wouldn't have been able to do it.   Cindy St. Hilaire:              Yeah. So your antisense oligonucleotide experiments, they were really nice. They showed, I think it was a four-week therapy, they showed that when you injected them expression of RNF130 went down by 90%. I think cholesterol in the animals was lowered by 50 points or so. Is this kind of a next viable option? And I guess related to that, cholesterol's extremely important for everything, right? Cell membrane integrity, our neurons, all sorts of things. Is it possible with something that is perhaps really as powerful as this to make cholesterol too low?   Elizabeth Tarling:             I think that what we know from PCSK9 gain and loss of function mutations is that you can drop your plasma cholesterol to very low levels and still be okay because there are people walking around with mutations that do that. I think RNF130 is a little different in that it's clearly regulatory in a homeostatic function in that it's ubiquitously expressed and it has this role in the liver to regulate LDL receptor availability, but there are no homozygous loss of function mutants people walking around, which tells us something else about how important it is in potentially other tissues and in other pathways. And we've only just begun to uncover what those roles might be.   So I think that as a therapy, it has great potential. We need to do a lot more studies to sort of move from rodent models into more preclinical models. But I do think that the human data tell us that it's really important in other places too. And so yeah, we need to think about how best it might work as a therapy. If it's combinatorial, if it's dosed. Those are the types of things that we need to think about.   Cindy St. Hilaire:              Yeah, it's really exciting. Do you know, are there other protein targets of RNF130? Is that related to my next question of what is next?   Elizabeth Tarling:             I mean, so I should point out, so Bethan unfortunately left the lab last year for a position at Amgen where she's working on obesity and metabolic disease. But before she left, she did two very, very cool experiments searching for new targets or additional targets of RNF130. Starting in the liver, but hopefully we'll move those into other tissues. And so she did gain of function RNF130 versus what loss of function we have of RNF130, and she did specific mass spec analysis of proteins that are ubiquitinated in those different conditions. And by overlaying those data sets, we're hoping to carve out new additional targets of RNF130. And there are some, and they're in interesting pathways, which we have yet to completely test, but definitely there are additional pathways, at least when you overexpress and reduce expression. Now, whether they turn out to be, again, bonafide in vivo, actual targets that are biologically meaningful is sort of the next step.   Cindy St. Hilaire:              Yeah. Well, I'm sure with your very rigorous approach, you are going to find out and hopefully we'll see it here in the future. Dr Elizabeth Tarling and Dr Bethan Clifford, thank you so much for joining me today. I really enjoyed this paper. It's a beautiful study. I think it's a beautiful example, especially for trainees about kind of thoroughly and rigorously going through and trying to test your hypothesis. So thanks again.   Elizabeth Tarling:             Thank you.   Bethan Clifford:               Thank you very much.   Cindy St. Hilaire:              That's it for the highlights from the March 31st and April 14th issues of Circulation Research. Thank you for listening. Please check out the Circulation Research Facebook page and follow us on Twitter and Instagram with the handle @CircRes, and #DiscoverCircRes. Thank you to our guests, Dr Liz Tarling and Dr Bethan Clifford.   This podcast is produced by Ishara Ratnayaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. I'm your host, Dr Cindy St. Hilaire, and this is Discover CircRes, you're on-the-go source for the most exciting discoveries in basic cardiovascular research.   This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors or of the American Heart Association. For more information, visit ahajournals.org.  

Did you know that household Tylenol is one of the most common causes of both intentional and unintentional toxicity in the pediatric population? Dr. George Hsu, a Pediatric Emergency Physician, joins Dr. Rebecca Yang and Medical Students Morgan Franklin and Ifrah Waris to discuss the evaluation and management for acetaminophen overdose in a pediatric patient.  Specifically, they will:  Review the basic assessment skills and evaluation for a child presenting with a potential acetaminophen overdose Discuss the diagnostic options and monitoring of acetaminophen overdose Discuss how to use the Rumack-Matthew nomogram in the treatment of acetaminophen overdose Medications and treatments reviewed: N-acetylcysteine, activated charcoal, and gastric lavage Discuss the potential complications of acetaminophen overdose Special thanks to Dr. Rebecca Yang and Dr. Arden Conway for peer reviewing this episode. Special thanks to Dr. Rebecca Yang and Dr. Arden Conway for peer reviewing the discussion today.  FREE CME Credit (requires free sign-up): Link Coming Soon! References:  Agrawal S, Khazaeni B. Acetaminophen Toxicity. [Updated 2021 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441917/ Heard K. J. (2008). Acetylcysteine for acetaminophen poisoning. The New England journal of medicine, 359(3), 285–292. https://doi.org/10.1056/NEJMct0708278 Hinson JA. Mechanism of acetaminophen-induced liver toxicity. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. 3rd ed. London, England: Academic Press; 2013:305-330. Hon KL, Hui WF, Leung AKC. Antidotes for childhood toxidromes. Drugs in Context 2021; 10: 2020-11-4. DOI: 10.7573/dic.2020-11-4 Greene SL, Dargan PI, Jones AL. Acute poisoning: understanding 90% of cases in a nutshell. Postgrad Med J. 2005 Apr;81(954):204-16. doi: 10.1136/pgmj.2004.024794. PMID: 15811881; PMCID: PMC1743253. Lee J, Fan NC, Yao TC, Hsia SH, Lee EP, Huang JL, Wu HP. Clinical spectrum of acute poisoning in children admitted to the pediatric emergency department. Pediatr Neonatol. 2019 Feb;60(1):59-67. doi: 10.1016/j.pedneo.2018.04.001. Epub 2018 Apr 19. PMID: 29748113. Manov I, Motanis H, Frumin I, Iancu TC. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects. Acta Pharmacol Sin. 2006 Mar;27(3):259-72. doi: 10.1111/j.1745-7254.2006.00278.x. PMID: 16490160. Myers WC, Otto TA, Harris E, Diaco D, Moreno A. Acetaminophen overdose as a suicidal gesture: a survey of adolescents' knowledge of its potential for toxicity. J Am Acad Child Adolesc Psychiatry. 1992 Jul;31(4):686-90. doi: 10.1097/00004583-199207000-00016. PMID: 1644732. Park, B. K., Dear, J. W., & Antoine, D. J. (2015). Paracetamol (acetaminophen) poisoning. BMJ clinical evidence, 2015, 2101. Riordan M, Rylance G, Berry K. Poisoning in children 2: painkillers. Arch Dis Child. 2002 Nov;87(5):397-9. doi: 10.1136/adc.87.5.397. PMID: 12390909; PMCID: PMC1763068. Silberman J, Galuska MA, Taylor A. Activated Charcoal. [Updated 2022 Jul 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482294/ Shekunov, J., Lewis, C. P., Vande Voort, J. L., Bostwick, J. M., & Romanowicz, M. (2021). Clinical Characteristics, Outcomes, Disposition, and Acute Care of Children and Adolescents Treated for Acetaminophen Toxicity. Psychiatric Services, appi-ps. Sheridan DC, Hendrickson RG, Lin AL, Fu R, Horowitz BZ. Adolescent Suicidal Ingestion: National Trends Over a Decade. J Adolesc Health. 2017 Feb;60(2):191-195. doi: 10.1016/j.jadohealth.2016.09.012. Epub 2016 Nov 23. PMID: 27889404. Silberman J, Galuska MA, Taylor A. Activated Charcoal. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482294/ Runde TJ, Nappe TM. Salicylates Toxicity. [Updated 2021 Jul 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499879/ Yarema M, Chopra P, Sivilotti MLA, Johnson D, Nettel-Aguirre A, Bailey B, Victorino C, Gosselin S, Purssell R, Thompson M, Spyker D, Rumack B. Anaphylactoid Reactions to Intravenous N-Acetylcysteine during Treatment for Acetaminophen Poisoning. J Med Toxicol. 2018 Jun;14(2):120-127. doi: 10.1007/s13181-018-0653-9. Epub 2018 Feb 8. Erratum in: J Med Toxicol. 2018 Mar 12;: PMID: 29423816; PMCID: PMC5962465.  

Actinic keratoses are the second most common reason patients visit the dermatologist. In the first podcast of this educational program, Dr. Deborah Sarnoff, Clinical Professor of Dermatology, NYU, and President of the Skin Cancer Foundation, discusses the clinical characteristics of AK, including symptoms, histology, and risk for SCC development.

Host Dr. Steve Morris speaks with study lead investigator Helen Mackie about her important findings related to compensatory lymphatic drainage in lower extremity lymphedema, particularly among those with a history of cancer. The findings of this study suggest support for manual lymph drainage to move lymph to the contralateral inguinal drainage region.

This week, please join author Mads Liisberg and Guest Host Mercedes Carnethon as they discuss the article "Clinical Characteristics, Incidences, and Mortality Rates for Type A and B Aortic Dissections: A Nationwide Danish Population-Based Cohort Study from 1996 to 2016." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke, National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Poly Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, today's feature paper is about aortic dissections and it's the first nationwide population based study investigating the clinical characteristic, incidents, and mortality based on validated diagnosis of aortic dissection in a national patient registry. You want to hear more? Well, you have to just keep listening. Let's go on though first to discuss the other really important papers in today's issue, shall we? Dr. Greg Hundley: Absolutely. Dr. Carolyn Lam: You know what, Greg? I'm going to start while you grab a coffee. I want to talk about high sensitivity cardiac troponins and how they have allowed the use of strategies in the emergency department, for example, to rapidly rule out acute MI within one to three hours and potentially facilitate early discharge of low-risk patients. Now, the ability to rapidly rule out MI of course depends on the turnaround time of these high sensitivity cardiac troponin results from the central laboratory, which is often delayed due to specimen transport and handling and all these things. So, point-of-care assays can reduce this turnaround time by even 40 minutes, and early studies have actually used frozen plasma bio banks to assess these point-of-care assays... But no study has evaluated these point-of-care assays with fresh whole blood to safely rule out MI in the emergency department. That is until today's paper. So in today's study led by corresponding other Doctor Fred Apple from Hennepin Medical Center in Minneapolis, Minnesota and his team, they aimed to derive and validate an optimal high sensitivity cardiac troponin threshold concentration using whole blood point-of-care troponin eye assay on a single sample at presentation in the emergency department to identify patients at low risk of index MI for potential early discharge. Dr. Greg Hundley: Fascinating study Carolyn. So point-of-care testing, high sensitivity troponin from whole blood in the ED. So what did they find? Dr. Carolyn Lam: Among consecutive emergency department patients from two prospective observational studies with suspected acute coronary syndrome, a point-of-care, whole blood, high sensitivity cardiac troponin eye assay, the Atellica VTli provided a sensitivity of 98.9% and a negative predictive value of 99.5% for ruling out MI. A single measurement using a cutoff of less than four nanograms per liter for whole blood was successful in rapidly identifying patients at low risk of MI cardiac and all cause death and unplanned revascularization at 30 days. Dr. Greg Hundley: Very nice Carolyn, and could be quite practical. So Carolyn, my next paper comes to us from the world of preclinical science and it pertains to cardiac regeneration. So cardiac regeneration after injury is limited by the low proliferative capacity of adult mammalian cardiomyocytes. However, certain animals readily regenerate lost myocardium via process involving dedifferentiation, which unlocks their proliferative capacities. So inspired by this concept, these investigators led by Professor Patrick Hsieh from Academic Sinica, generated mice with inducible cardiomyocyte specific expression of the Yamanaka factors enabling adult cardiomyocyte reprogramming and dedifferentiation in vivo. Dr. Carolyn Lam: Wow. So what did they find, Greg? Dr. Greg Hundley: Right, Carolyn. So two days following induction, adult cardiomyocytes presented with a dedifferentiated phenotype, an increase proliferation in vivo. Microarray analysis revealed that the up-regulation of ketogenesis was central to this process. Now adenovirus driven HMGCS2 over-expression induced ketogenesis in adult cardiomyocytes and recapitulated cardiomyocyte dedifferentiation and proliferation observed during partial reprogramming. This same phenomenon was found to occur after myocardial infarction, specifically in the border zone tissue. And HMGCS2 knockout mice showed impaired cardiac function and response to injury, and so in summary, Carolyn, these data demonstrated the importance of HMGCS2 induced ketogenesis as a means to regulate metabolic response to cardiomyocyte injury, thus allowing cell dedifferentiation and proliferation as a regenerative response. Dr. Carolyn Lam: Wow, that's so cool. From cell regeneration to autoimmunity in this next paper. Now autoimmunity is increasingly recognized as a key contributing factor in heart muscle diseases. However, the functional features of cardiac autoimmunity in humans remain undefined due to the challenge of studying immune responses in situ. Now, these authors previously described a subset of c-Met expressing memory T lymphocytes, which preferentially migrate to cardiac tissue in mice and humans. In today's study, these authors led by co-corresponding authors, Dr. Federica Marielli-Berg and Saidi Mohidden from William Harvey Research Institute, Barts and the London Faculty of Medicine and Dentistry, and Queen Mary University of London, and their colleagues performed in-depth phenotyping of peripheral blood T cells in groups of patients with inflammatory and non-inflammatory cardiomyopathies, patients with non-cardiac autoimmunity and healthy controls... And they found that c-Met positive T cells were selectively increased in the circulation and in the myocardium of patients with inflammatory cardiomyopathies. The phenotype and function of c-Met positive T-cells were distinct from c-Met negative T cells, including preferential proliferation to cardiac myosin and co-production of multiple cytokines. Further, circulating c-Met positive T cell subpopulations in different heart muscle diseases identified distinct and overlapping mechanisms of heart inflammation. Furthermore, validation studies in experimental autoimmune myocarditis showed that elevations of auto-antigens specific c-Met positive T cells in peripheral blood, marked the loss of immune tolerance to the heart. Importantly, disease development could be halted by pharmacologic c-Met inhibition indicating a positive role for these c-Met positive T cells. Dr. Greg Hundley: All right, Carolyn, as you always ask me. So what's the take home message here? Dr. Carolyn Lam: This study demonstrates that the detection of circulating c-Met positive T cells may have utility in the diagnosis and monitoring of adaptive cardiac inflammation and additionally defined new targets for therapeutic intervention when cardiac autoimmunity causes or contributes to progressive cardiac injury... And this is discussed in an editorial by doctors at Abplanalp, Merten, and Dimmeler. Dr. Greg Hundley: Very nice, Carolyn. Wow. More fantastic preclinical science. Well, in the mail of the bag today, there is a Research Letter by Professor Burr entitled “Cannabis Inhalation Acutely Reduces Muscle Sympathetic Nerve Activity in Humans.” Dr. Carolyn Lam: There's an ECG Challenge by Dr. Reddy entitled “Shortness of Breath and Near Syncope During Exertion In a Child, When Patient Worry Syndrome.” There's also a Perspective by Dr. Weitz on what is the future of Factor 11 inhibitors. Dr. Greg Hundley: Well Carolyn, I'm looking forward to learning more about aortic dissections and that large Danish population-based study. Wow. Dr. Carolyn Lam: That's great. Let's go Greg. Dr. Mercedes Carnethon: Well, welcome to this episode of Circulation on the Run. My name is Mercedes Carnethon, an Associate Editor of Circulation, and Professor and Vice Chair of Preventive Medicine at Northwestern University. I'm really excited today to be here with the senior author of a really exciting paper that we're featuring on clinical characteristics, incidences and mortality rates for aortic dissections type A and B, a nationwide Danish population-based cohort study, and we have with us today Mads Liisberg. So welcome today. Dr. Mads Liisberg: Thank you. Dr. Mercedes Carnethon: So thank you so much for joining us and really thank you for sharing your important research with Circulation. This topic is so critically important, particularly given the high mortality rates associated with aortic dissections. Can you tell us a little bit about the work that you and your co-authors did in this important space? Dr. Mads Liisberg: Yes. Well actually the work originated when I started my PhD thesis and we got a registry data dump from the Danish medical registries and we found that almost none of our patients in the registry were registered with a specific aortic dissection code. So we did a validation study on the same time period from 1999 to 2006 where we went through all these medical records to ensure that we had the right aortic dissection TC 10 codes on population. Then we went a bit further and looked at the clinical characteristics of this patient, 'cause that's one of the really major things about Danish medical registries in our country, is that we have access to not only every patient's specific in hospital contacts, but also their medicine abuse, their drug use based on a TC code. So we can go really deep into each and everyone's drug history. When we did this study, we wanted to find out if the incidence rates during this timeframe had changed, which we find that it did, but also looking at mortality rates because, as you said, it's really high risk disease to be diagnosed with. So that's more the rationale for this study. Dr. Mercedes Carnethon: Thank you so much for sharing that. Certainly we know that the mortality rates from this are very high. I note that you report some changes over time between 1996 and 2016 in the incidents of these types of aortic dissections. So what did you find about the patterns of change in type A aortic dissections? Dr. Mads Liisberg: We found that it almost doubled from the beginning of our time period to the last, and the question is why is this? 'Cause that's one of the thing that the data doesn't reveal. We are only able to see that the incidence actually rises, but is it because that they are underdiagnosed in the beginning? Or is it because that we are better diagnosing in the end of the study that really are progressed? Dr. Mercedes Carnethon: That's a good question. I noted that when you studied the correlates of aortic dissection, you identified a number of characteristics and what stood out to me was the finding about the strong association of hypertension. I'm less aware of patterns of hypertension in the Danish population. Do you think that the changes in the prevalence of hypertension in the population contributed at all to these findings? Dr. Mads Liisberg: Well, most certainly, 'cause when you look at the prevalence of hypertension throughout any person's lifespan, the older they get the more likely they are to suffer from hypertension, and the Danish population has aged quite a lot in recent years. So I think that's one of the main reasons we find this, and also that most of our arctic dissection patients are actually quite old, which would correlate with hypertension as well. Dr. Mercedes Carnethon: One thing I really like, and you pointed this out, is really the richness of the data that you have in your health system, and I wonder, just going even a little deeper on the hypertension question, given that it is the most common medical diagnosis worldwide, were you able to study characteristics of hypertension that would be more strongly associated with aortic dissection? So for example, duration of hypertension, severity, prevalence of hypertension control? Dr. Mads Liisberg: That's actually a funny question 'cause the last study of my thesis, which hasn't been published yet or even submitted for that fact, examines the correlation between use and the risk of arctic dissection. On a very specific level, the way that hypertension is treated mostly in Denmark is with your general practitioner. So the way that we examine in studies like these, is that we look at prescription drug use. So if we find that an individual has a TC codes corresponding with anti-hypertensive drugs, then we are able to code them as hypertensive patients. Dr. Mercedes Carnethon: Okay, thank you for that. I always... I'm an epidemiologist myself, so I really love to see great population science studies and this registry is large, you have long-term follow up and you've got a great deal of data, but those people who feel as though it's obviously not appropriate to make causal conclusions around epidemiology and that perhaps epidemiologic findings shouldn't be driving clinical decision-making. In response to that, I think I would pose the question to you, which is how do you see clinicians and providers using this information from your observational study? Dr. Mads Liisberg: I think that's rather difficult. One of the findings that we present is to pose it over mortality for type B dissections when we exclude the 30-day mortality, but then we show that type A dissections have almost a corresponding mortality rate compared to a hypertensive cohort... And this finding is difficult to draw any clinical conclusions from, but there's actually a Danish randomized controlled trial just starting up in the next year. I think it's called the Sunday trial, where they will include all uncomplicated type B dissections and randomize them for treatment or no treatment, and the issue here is that you'll probably be over-treating some patients and under-treating others, but this discussion with the uncomplicated type B dissection has been ongoing for so many years. So it's difficult for me to just give one golden answer. Dr. Mercedes Carnethon: Certainly, and I appreciate the caution as we certainly don't want to overstep our findings. You did make a recommendation in the conclusion that it might be beneficial to treat type B aortic dissections more aggressively. Is this what you're alluding to, based on the other study that you're referencing? Dr. Mads Liisberg: Yes, yes, definitely. We see some clinicians being more cautious treating type B dissections with a TIVA or a surgery. So it's a difficult thing when they're uncomplicated, why treat them? But they can't be or become complicated quite easily and fast and then it's a difficult thing, because should you have treated them earlier? Or do you need to treat them now in their acute phase? Or wait for a chronic phase? It's a really good question. Dr. Mercedes Carnethon: No, I appreciate that and what I really love are the types of research studies that leave you with many more questions and next steps, and so I would like to really sort of bring us to a close with the big picture question, which is what do you see as the next steps in this line of research, given really what we all agree on is a very significant clinical problem. Dr. Mads Liisberg: We would really like to expand our database with even more clinical data as of now and include any image diagnostics for our cohort. So we're might be able to see any trends in our modulation before the dissection occurs. If any of our patients have any diagnostics done prior to being diagnosed. Dr. Mercedes Carnethon: I really want to thank you today for spending time talking with us. I know that our readers rarely have an opportunity to hear from everybody behind the scenes views on what the rationale was for carrying out a paper and really how the authors themselves hope that the paper will be used. So I really thank you for sharing that with us today, Matts, on behalf of your co-authors, this has been really a wonderful conversation, and thank you again for sharing your research with the journal, Circulation. Dr. Mads Liisberg: Oh, thank you for having me in for accepting our paper. Dr. Mercedes Carnethon: So thank you so much to our listeners for listening to us on this episode of Circulation on the Run. Please tune in next week as we will have more exciting insights. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Welcome to The Brain Podcast - the official podcast for the journal Brain and sister journal Brain Communications. In this episode we are joined by Professor Soon-Tae Lee to discuss his review article entitled Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes. Read the full article on the Brain website: https://doi.org/10.1093/brain/awac166 Maarten Titulaer and Robin van Steenhoven wrote an excellent commentary on the article https://doi.org/10.1093/brain/awac338 We were lucky to have Maarten join us in this podcast discussion. This episode was hosted, edited and produced by Xin You Tai; co-hosted by Sarosh Irani; co-produced by Joanne Bell; original music by Ammar Al-Chalabi.

Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. Diffuse alveolar hemorrhage in antiphospholipid syndrome Dr. Eric Dein discusses Abstract 0675 at ACR22 Convergence. Abstract 0675: Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at ACR22 Convergence. Abstract 0872: Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis Gender differences in Axial Spondyloarthritis Dr. Antoni Chan covered abstracts 0497 and 1614 at ACR22 Convergence in Philadelphia, PA. Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE Dr. Sheila Reyes discusses abstract 1654 at ACR22 Convergence.  Abstract 1654: Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence.  Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence.  Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis

We received a question on Instagram about what sensory strategies we would recommend to help a child who has lower cognitive abilities or who is non-speaking or pre-verbal.We've had many, many clients who had learning disabilities, used AAC devices because they didn't communicate verbally, or who struggled overall with communication - expressive and receptive. In this episode, we're going to draw from our own personal experiences as well as research! Be sure to check out the show notes on our blog at  Harkla.Co/Podcast.Brought To You By HarklaThis podcast is brought to you by Harkla.  Our mission at Harkla is to help those with special needs live happy and healthy lives. We accomplish this through high-quality sensory products & child development courses.Podcast listeners get 10% off their first order at Harkla with the discount code "sensory". Head to Harkla.co/sensory to start shopping now.LinksLooking for more in-depth help? Sign up for 2-on-1 Mentoring With Us!!FREEBIES!All Things Sensory Podcast Instagram Harkla YouTube ChannelHarkla Website Harkla InstagramEp. 25 Executive Functioning Ep. 107 Interactive Metronome Ep. 139 Incorporating Speech into Play YouTube - Build an Obstacle CourseWhat are Cognitive Deficits?Clinical Characteristics of Intellectual DisabilitiesEncyclopedia of ASD - Preverbal CommunicationEffects of Vestibular Stimulation on Spontaneous Use of Verbal Language The Immediate Effects of Vestibular Stimulation on Language PerformanceThe Beneficial Effect of Vestibular StimulationHappy Hug Sensory Tube Interactive Metronome Homedics Pure Therapy Head Massager 

Why do patients stop clozapine?  This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about Premium Membership here Earn 0.5 CMEs: Quick Take Vol. 38 Demographic and Clinical Characteristics of Patients Who Recommence Clozapine Following Therapy Interruptions

1: Jaclyn Megan Sions, PT DPT PhD, Clinical Research Scientist, Assistant Professor in Physical Therapy, University of Delaware, Newark, DE Characterizing Pain among Adolescents and Young Adults with Arthrogryposis Multiplex Congenita Primary study objectives were to characterize pain and explore differences between adolescents and adults with arthrogryposis multiplex congenita and evaluate associations between pain-related outcomes and mobility. 2: Diana Early, PT PhD PCS, Children's Health, Dallas, TX The Journey: Parental Expectations and Perceptions of Therapy Services for Children with Down Syndrome The researchers identified and described parents' expectations and perceptions of therapy services received by their children with Down syndrome 3: Courtney M Goldsbury, PT DPT PCS, Cincinnati Children's Hospital Medical Center, Cincinnati, OH Infants with Congenital Muscular Torticollis Requiring Supplemental Physical Therapy Interventions To describe supplemental intervention frequency in infants with congenital muscular torticollis and compare groups of infants who received first-choice intervention only to infants who received supplemental intervention. 4: Kelly R Greve, PT DPT PhD PCS, Cincinnati Children's Hospital Medical Center, Division of Occupational Therapy and Physical Therapy, Cincinnati, OH Infants with Congenital Muscular Torticollis: Demographic Factors, Clinical Characteristics, and Physical Therapy Episode of Care 5: Luke Wakely, PhD, MHSc(Paed Physio), BAppSc(Physio), Department of Rural Health, The University of Newcastle, Tamworth, NSW, Australia A Survey of Parents' and Carers' Perceptions of Parenting a Child with Developmental Dysplasia of the Hip To explore parents' and carers' perceptions of parenting a child with developmental dysplasia of the hip. 6: Rebecca Kern PT DPT, Dept of Rehab & Neurosciences, Children's Healthcare of Atlanta, Atlanta, GA, Student Support Programs and Services Seated outcome measures in children with Duchenne Muscular Dystrophy To study the feasibility of seated trunk strength using hand held dynamometry and care giver reported subjective functional independence measures in boys with Duchenne muscular dystrophy. 7: Mitch Wolden, PT DPT PhD, Physical Therapy Program, University of Jamestown, Fargo, ND Student Self-Efficacy in Pediatrics: Evaluation and Modification of the Pediatric Communication and Handling Self-Efficacy Scale Our purpose was to examine the reliability and validity of the Pediatric Communication and Handling Self-Efficacy Scale and develop a shorter, modified version. 8: Kimberly D Wynarczuk, PT PhD MPH, Moravian University, Bethlehem, PA The How and the Why of Including Children: Experiential Learning in Teaching Physical Therapy Students This study describes experiential learning activities with children and the rationale for using experiential learning. 9: Jennifer Price PT DPT, Director of Clinical Education & Assistant Professor, Department of Physical Therapy, Lebanon Valley College, Annville, PA, and Tonya Y. Miller, PT, DPT, PhD Program Lead, Doctor of Physical Therapy Program, Harrisburg University of Science & Technology The Impact of an Overnight Summer Camp on the Quality of Life for Individuals Who Require Ventilatory Support. The purpose of this study was to examine the perceptions of a camp experience for individuals who require ventilatory support.

Commentary by Dr. Valentin Fuster

Do you or someone you love struggle with ADHD and don't know what could help with symptoms associated with it? Are you curious of what the root cause may be? We discuss some possible dietary links and how to alleviate symptoms in this most recent podcast. We also recognize the complexity of both the gut microbiome and ADHD, but we are here to discuss patterns found in recent research. We take a short, but deep, dive into: What may lead to higher incidences of ADHD? What are the biomarkers that research is pointing to higher rates of ADHD? What nutritional steps may help influence lower ADHD rates? What supplementation may be helpful to reduce ADHD symptoms? Will supplementation help increase weight gain? Is supplementation safe? You can find the short, 15-minute podcast at empowerednutrition.health/adhdandguthealth Want to try supplements mentioned in the podcast? No problem! You can check them out here and recieve 10% off! Products mentioned were: Klaire Labs' Ther-Biotic Factor 4, Designs for Health's ProbioMed 50, and Integrative Therapeutics' Pro-Biome 50B Are you struggling to heal and revamp your metabolism? Don't worry! We have recently launched our Lean for Life Membership phase one called “Heal” on where you will be empowered to reverse previous metabolic damage with the assistance of our team of Registered Dietitian Nutritionists. Find out more details here. Enjoying the podcast? Please review the Empowered Nutrition Podcast on Apple Podcasts or wherever you listen! Then, send me a screenshot of your positive review to podcast@empowerednutrition.health or a DM on Instagram (empowerednutrition.health). Include a brief description of what you're working on with your health and/or nutrition and I'll send you a free custom meal plan! Interested in working on your personal health goals? Book a free chemistry call to discuss your story and see if we're a good fit here. Love free products? Get a free one year supply of Vitamin D and five free travel packs with your first purchase of Athletic Greens' AG1 nutritional supplement when you visit athleticgreens.com/empowered Do you have questions you would like answered on the Empowered Nutrition podcast? You can propose your questions/ideas here or reach out to me at podcast@empowerednutrition.health I can't wait to hear from you. Enjoy listening! Want to dive deeper into the research studies mentioned in the podcast? You can check them out here: Cenit MC, Nuevo IC, Codoñer-Franch P, Dinan TG, Sanz Y. Gut microbiota and attention deficit hyperactivity disorder: new perspectives for a challenging condition. Eur Child Adolesc Psychiatry. 2017 Sep;26(9):1081-1092. doi: 10.1007/s00787-017-0969-z. Epub Bull-Larsen S, Mohajeri MH. The Potential Influence of the Bacterial Microbiome on the Development and Progression of ADHD. Nutrients. 2019 Nov 17;11(11):2805. doi: 10.3390/nu11112805. PMID: 31744191; PMCID: PMC6893446. Kalenik A, Kardaś K, Rahnama A, Sirojć K, Wolańczyk T. Gut microbiota and probiotic therapy in ADHD: A review of current knowledge. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110277. doi: 10.1016/j.pnpbp.2021.110277. Epub 2021 Feb 6. PMID: Wang LJ, Yang CY, Kuo HC, Chou WJ, Tsai CS, Lee SY. Effect of Bifidobacterium bifidum on Clinical Characteristics and Gut Microbiota in Attention-Deficit/Hyperactivity Disorder. J Pers Med. 2022 Feb 7;12(2):227. doi: 10.3390/jpm12020227. PMID: 35207715; P

In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Seroprevalence of Infection-Induced Antibodies (CDC)  Authorization for Vaccine in Young Children Filed (Moderna) Public Health Impact of Vaccines in US (BMJ) FDA authorizes first approved treatment for children (FDA) Phase 2 Data for Sabizabulin (Veru Pharma)  Clinical Characteristics of Post Infection Inflammation (The Lancet) Fact Sheet for Providers on Evusheld (FDA) Fact Sheet for Providers on Paxlovid (FDA) Provider Referral for EvuSheld (Northwell Health) Contribute to ASTMH fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 895 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Olá, bem-vindo à Tribo TDAH, o podcast com hiperfoco na sua vida! Hoje nós vamos falar sobre TDAH e pessoas trans, então venha entender sobre expressão e identidade de gênero e como isso pode afetar na nossa saúde mental do TDAH quando não acolhido.Descubra como pessoas trangêneros podem ser dos mais diferentes tipos e como a disforia de gênero sofre grande impacto do nosso Transtorno de Déficit de Atenção e Hiperatividade desde a primeira infância.#TDAH#TDAHpodcasters#PcDPodcasters#OPodcastÉDelas#MulheresPodcasters---**Tribo TDAH na mídia**- TV Brasil - Caminhos da Reportagem - Um jeito TDAH de ser https://youtu.be/oHkQj1Ar5DA---**Seja um TDAHyper e ajude a Tribo TDAH a crescer!**- Tribo TDAH no Apoia.se https://apoia.se/tribotdah - Tribo TDAH no PicPay https://picpay.me/triboTDAH---**Links de referência**- Mas afinal, qual o significado de LGBTQQICAPF2K+ e outras siglas como LGBTQ+? https://razoesparaacreditar.com/significado-lgbtqqicapf2k/- Identidade de Gênero: o que precisamos saber sobre? https://www.dci.com.br/dci-mais/noticias/identidade-de-genero/10870/- “Gender Diversity and Neurodiversity: How to Support a Child, Teen, or Young Adult with ADHD as They Explore Gender” https://www.additudemag.com/webinar/lgbtq-transgender-adhd-gender-diversity-podcast-350/- ADHD Voices: Corrin https://adhdsurprise.com/tag/transgender/- Caring for the Transgender Adolescent: It Takes a Village https://www.eunetworkadultadhd.com/caring-for-the-transgender-adolescent-it-takes-a-village/- Caring for the Transgender Adolescent: It Takes a Village https://www.eunetworkadultadhd.com/caring-for-the-transgender-adolescent-it-takes-a-village/ - Caring for the Transgender Adolescent: It Takes a Village https://pubmed.ncbi.nlm.nih.gov/31107766/- Gender dysphoria and attention problems: possible clue for biological underpinnings https://www.tandfonline.com/doi/full/10.1080/24750573.2017.1354417- ADHD and Depressive Disorders More Frequently Diagnosed in Transgender Youth https://chadd.org/adhd-in-the-news/adhd-and-depressive-disorders-more-frequently-diagnosed-in-transgender-youth/- Mental Health of Transgender and Gender Nonconforming Youth Compared With Their Peers https://pediatrics.aappublications.org/content/141/5/e20173845- ADHD and Depressive Disorders More Frequently Diagnosed in Transgender Youth https://www.technologynetworks.com/neuroscience/news/adhd-and-depressive-disorders-more-frequently-diagnosed-in-transgender-youth-299702- Transgender youth more often diagnosed with mental health conditions https://www.kp-scalresearch.org/transgender-youth-more-often-diagnosed-with-mental-health-conditions/- Sociodemographic and Clinical Characteristics of Transgender Adults in Australia https://www.liebertpub.com/doi/full/10.1089/trgh.2018.0019- Prevalence of Autism Spectrum Disorder and Attention-Deficit Hyperactivity Disorder Amongst Individuals with Gender Dysphoria: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31732891/---**Episódios relacionados**- PQPCast #200 - Por que TDAHI vive entre a imaginação e a realidade acelerada? http://www.pqpcast.com/blog/200-tdahi- Tribo TDAH #01 - TDAH, mitos e verdades http://www.pqpcast.com/blog/tribotdah-1-mitosverdades - Tribo TDAH #02 - TDAH e genialidade http://www.pqpcast.com/blog/tribotdah-2-genialidade- Tribo TDAH #03 - TDAH e História http://www.pqpcast.com/blog/tribotdah-3-historia - Tribo TDAH #04 - TDAH e desequilíbrio emocional http://www.pqpcast.com/blog/tribotdah-4-desequilibrio-emocional- Tribo TDAH #05 - TDAH e diagnóstico http://www.pqpcast.com/blog/tribotdah-5-diagnostico - Tribo TDAH #06 - TDAH e dopamina http://www.pqpcast.com/blog/tribotdah-6-dopamina- Tribo TDAH #07 - TDAH e criatividade http://www.pqpcast.com/blog/tribotdah-7-criatividade - Tribo TDAH #08 - TDAH e insônia http://www.pqpcast.com/blog/tribotdah-8-insonia- Tribo TDAH #09 - TDAH e rejeição http://www.pqpcast.com/blog/tribotdah-9-rejeicao - Tribo TDAH #10 - TDAH, desastrados e desequilíbrio http://www.pqpcast.com/blog/tribotdah-10-desastrado-desequilibrio - Tribo TDAH #11 - TDAH e miopia temporal http://www.pqpcast.com/blog/tribotdah-11-tempo - Tribo TDAH #12 - TDAH e espectro de intensidade http://www.pqpcast.com/blog/tribotdah-12-espectro - Tribo TDAH #13 - TDAH e hiperfoco (parte 1) http://www.pqpcast.com/blog/tribotdah-13-hiperfoco1- Tribo TDAH #14 - TDAH e hiperfoco (parte 2) http://www.pqpcast.com/blog/tribotdah-14-hiperfoco2- Tribo TDAH #15 - TDAH e 3 classificações (Parte 1) http://www.pqpcast.com/blog/tribotdah-15-3classificacoes1- Tribo TDAH #16 - TDAH e 3 classificações (Parte 2) http://www.pqpcast.com/blog/tribotdah-16-3classificacoes2- Tribo TDAH #17 - TDAH e 7 subtipos (parte 1) http://www.pqpcast.com/blog/tribotdah-17-7subtipos-1 - Tribo TDAH #18 - TDAH e 7 subtipos (parte 2) http://www.pqpcast.com/blog/tribotdah-18-7subtipos-2- Tribo TDAH #19 - TDAH e perfeccionismo (parte 1) http://www.pqpcast.com/blog/tribotdah-19-perfeccionismo-1- Tribo TDAH #20 - TDAH e perfeccionismo (parte 2) http://www.pqpcast.com/blog/tribotdah-20-perfeccionismo-2- Tribo TDAH #21 - TDAH e motivação (parte 1) http://www.pqpcast.com/tribo-tdah/21-motivacao-1 - Tribo TDAH #22 - TDAH e motivação (parte 2) http://www.pqpcast.com/tribo-tdah/22-motivacao-2 - Tribo TDAH #23 - TDAH e empatia (parte 1) http://www.pqpcast.com/tribo-tdah/23-empatia-1- Tribo TDAH #24 - TDAH e empatia (parte 2) http://www.pqpcast.com/tribo-tdah/24-empatia-2- Tribo TDAH #25 - TDAH e comunidade (Especial aniversário 1 ano - Parte 1) http://www.pqpcast.com/tribo-tdah/25-comunidade-1 - Tribo TDAH #26 - TDAH e comunidade (Especial aniversário 1 ano - Parte 2) http://www.pqpcast.com/tribo-tdah/26-comunidade-2 - Tribo TDAH #27 - TDAH e comunidade (Especial aniversário 1 ano - Parte 3) http://www.pqpcast.com/tribo-tdah/27-comunidade-3 - Tribo TDAH #28 - TDAH e hipersensibilidade (parte 1) http://www.pqpcast.com/tribo-tdah/28-hipersensibilidade-1 - Tribo TDAH #29 - TDAH e hipersensibilidade (parte 2) http://www.pqpcast.com/tribo-tdah/29-hipersensibilidade-2 - Tribo TDAH #30 - TDAH e mulheres (Roda de conversa - Parte 1) #OPodcastÉDelas http://www.pqpcast.com/tribo-tdah/30-mulher-1 - Tribo TDAH #31 - TDAH e mulheres (Roda de conversa - Parte 2) #OPodcastÉDelas http://www.pqpcast.com/tribo-tdah/31-mulher-2 - Tribo TDAH #32 - TDAH e mentiras (Parte 1) http://www.pqpcast.com/tribo-tdah/32-mentira-1 - Tribo TDAH #33 - TDAH e mentiras (Parte 2) http://www.pqpcast.com/tribo-tdah/33-mentira-2 - Tribo TDAH #34 - TDAH e quarentena (Roda de conversa especial) http://www.pqpcast.com/tribo-tdah/34-quarentena - Tribo TDAH #35 - TDAH e trabalho (Parte 1) http://www.pqpcast.com/tribo-tdah/35-trabalho-1 - Tribo TDAH #36 - TDAH e trabalho (Parte 2) http://www.pqpcast.com/tribo-tdah/36-trabalho-2- Tribo TDAH #37 - TDAH e diagnóstico aplicado (Parte 1) http://www.pqpcast.com/tribo-tdah/37-diagnostico-aplicado-1- Tribo TDAH #38 - TDAH e diagnóstico aplicado (Parte 2) http://www.pqpcast.com/tribo-tdah/38-diagnostico-aplicado-2 - Tribo TDAH #39 - TDAH, relacionamento e amizade (Parte 1) http://www.pqpcast.com/tribo-tdah/39-relacionamento-amizade-1- Tribo TDAH #40 - TDAH, relacionamento e amizade (Parte 2) http://www.pqpcast.com/tribo-tdah/40-relacionamento-amizade-2- Tribo TDAH #41 - TDAH, relacionamento e amizade (Parte 3) http://www.pqpcast.com/tribo-tdah/41-relacionamento-amizade-3- Tribo TDAH #42 - TDAH e sonhos (Parte 1) http://www.pqpcast.com/tribo-tdah/42-sonho-1 - Tribo TDAH #43 - TDAH e sonhos (Parte 2) http://www.pqpcast.com/tribo-tdah/43-sonho-2 - Tribo TDAH #44 - TDAH e sonhar acordado (maladaptive daydreaming) (Parte 1) http://www.pqpcast.com/tribo-tdah/44-sonhar-acordado-1 - Tribo TDAH #45 - TDAH e sonhar acordado (maladaptive daydreaming) (Parte 2) http://www.pqpcast.com/tribo-tdah/45-sonhar-acordado-2 - Tribo TDAH #46 - TDAH, flexibilidade cognitiva e rigidez de pensamento (Parte 1) http://www.pqpcast.com/tribo-tdah/46-flexibilidade-cognitiva-rigidez-pensamento-1- Tribo TDAH #47 - TDAH, flexibilidade cognitiva e rigidez de pensamento (Parte 2) http://www.pqpcast.com/tribo-tdah/47-flexibilidade-cognitiva-rigidez-pensamento-2- Tribo TDAH #48 - TDAH, finanças, compra por impulso e Black Friday (Parte 1) http://www.pqpcast.com/tribo-tdah/48-financa-compra-impulso-black-friday-1 - Tribo TDAH #49 - TDAH, finanças, compra por impulso e Black Friday (Parte 2) http://www.pqpcast.com/tribo-tdah/49-financa-compra-impulso-black-friday-2 - Tribo TDAH #50 - TDAH e Transtorno da Acumulação (Parte 1) http://www.pqpcast.com/tribo-tdah/50-acumuladores-1- Tribo TDAH #51 - TDAH e Transtorno da Acumulação (Parte 2) http://www.pqpcast.com/tribo-tdah/51-acumuladores-2- Tribo TDAH #52 - TDAH e lado positivo (Roda de conversa - Aniversário 2 anos) (Parte 1) http://www.pqpcast.com/tribo-tdah/52-TDAH-positivo-1 - Tribo TDAH #53 - TDAH e lado positivo (Roda de conversa - Aniversário 2 anos) (Parte 2) http://www.pqpcast.com/tribo-tdah/53-TDAH-positivo-2- Tribo TDAH #54 - TDAH e procrastinação (Parte 1) http://www.pqpcast.com/tribo-tdah/54-procrastinar-1- Tribo TDAH #55 - TDAH e procrastinação (Parte 2) http://www.pqpcast.com/tribo-tdah/55-procrastinar-2- Tribo TDAH #56 - TDAH e procrastinação (Parte 3 - Roda de Conversa) #OpodcastÉDelas2021 http://www.pqpcast.com/tribo-tdah/56-procrastinar-roda-conversa-3- Tribo TDAH #57 - TDAH e procrastinação (Parte 4 - Roda de Conversa) #OpodcastÉDelas2021 http://www.pqpcast.com/tribo-tdah/57-procrastinar-roda-conversa-4- Tribo TDAH #58 - TDAH, permanência e constância de objeto (Parte 1) http://www.pqpcast.com/tribo-tdah/58-permanencia-objeto-constancia-objeto-1- Tribo TDAH #59 - TDAH, permanência e constância de objeto (Parte 2) http://www.pqpcast.com/tribo-tdah/59-permanencia-objeto-constancia-objeto-2- Tribo TDAH #60 - TDAH e memória (Parte 1) http://www.pqpcast.com/tribo-tdah/60-memoria-1- Tribo TDAH #61 - TDAH e memória (Parte 2) http://www.pqpcast.com/tribo-tdah/61-memoria-2- Tribo TDAH - TDAH Explica #01 - Por que TDAHs têm tanto medo de falhar? http://www.pqpcast.com/tribo-tdah/tdah-explica-1-medo-de-falhar- Tribo TDAH - TDAH Explica #02 - Por que TDAHs se sabotam? http://www.pqpcast.com/tribo-tdah/tdah-explica-2-autossabotagem- Tribo TDAH - TDAH Explica #03 - TDAHs podem viver sem medicação? http://www.pqpcast.com/tribo-tdah/tdah-explica-3-medicacao-terapia- Tribo TDAH - TDAH Explica #04 - TDAH tem relação com problemas de tireoide? http://www.pqpcast.com/tribo-tdah/tdah-explica-4-tireoide- Tribo TDAH - TDAH Explica #05 - Atividades manuais, fidgets e stims ajudam na atenção do TDAH? http://www.pqpcast.com/tribo-tdah/tdah-explica-5-atividade-manual-fidget-stim-atencao-foco- Tribo TDAH - TDAH Explica #06 - COVID-19 causa TDAH? Quais efeitos no transtorno? (Parte 1) http://www.pqpcast.com/tribo-tdah/tdah-explica-6-covid-19-1- Tribo TDAH - TDAH Explica #07 - COVID-19 causa TDAH? Quais efeitos no transtorno? (Parte 2) http://www.pqpcast.com/tribo-tdah/tdah-explica-7-covid-19-2- Tribo TDAH - TDAH Entrevista #01 - Doutora Drag, vida acadêmica e LGBT http://www.pqpcast.com/tribo-tdah/tdah-entrevista-doutora-drag-lgbt-vida-academica- Tribo TDAH - TDAH Entrevista #02 - Dra. Ana Beatriz Barbosa Silva, Fiuk, cotidiano e sentimentos http://www.pqpcast.com/tribo-tdah/tdah-entrevista-ana-beatriz-barbosa-silva-fiuk-bbb- Tribo TDAH - TDAH Entrevista #03 - Carla Manso, maternidade, body positive e autoestima #OPodcastÉDelas2021 http://www.pqpcast.com/tribo-tdah/tdah-entrevista-3-carla-manso-maternidade-aceitacao-autoestima- Tribo TDAH - TDAH Entrevista #04 - Izzy Nobre, Conteúdo, Mudanças e TDAH na mídia http://www.pqpcast.com/tribo-tdah/tdah-entrevista-4-izzy-nobre-conteudo-mudanca-cultura-pop- PQPCast #196 - Por que ansiedade é o limiar entre evolução humana e o transtorno? http://www.pqpcast.com/blog/196-ansiedade- PQPCast #216 - Por que a gamificação combate os vilões da saúde mental na vida real? http://www.pqpcast.com/blog/216-gamificacao- PQPCast #218 - Por que cotas abrem acesso a espaços de direito de pessoas com deficiência, negros, trans e TDAHs? http://www.pqpcast.com/blog/218-cotas---Assine nosso Feed da Tribo TDAH http://www.pqpcast.com/tribo-tdah/?format=rss Spotify Tribo TDAH https://open.spotify.com/show/2bgtfNUQcF4ZgZZWKvBX2G Deezer Tribo TDAH https://www.deezer.com/us/show/1040242**Instagram**- Tribo TDAH (@tribotdah) https://www.instagram.com/tribotdah/ **Twitter**- Tribo TDAH (triboTDAH) https://twitter.com/TriboTDAH - #PodcasterProcura (@PodProcura) https://twitter.com/podprocura - Thata Finotto (@thata_finotto) https://twitter.com/thata_finotto **Facebook**- Página Tribo TDAH https://www.facebook.com/TriboTDAH - Página Podcaster Procura https://www.facebook.com/PodProcura/ **Telegram**- Canal #PodcasterProcura (@PodProcura) https://t.me/PodProcura Edição: Andrey Mattos https://twitter.com/andreymatttosApoio cultural: Kairós Soluções Empresariais http://kairoscorp.com.br/

Certified wildlife tracker Sage Raymond, is completing her Masters of Science studying Urban-adapted Coyote ecologies in Edmonton. She has been working with colleagues on the Edmonton Urban Coyote Project studying the patterns and behaviours of these urbanized Coyotes in hopes to be better able to predict, and reduce some of the possible problems or conflicts which could occur between these wilder animals and human/pet populations. Additionally, we talk about the use of tracking as a useful, non-invasive tool for studying wildlife, novel non-native zoonotic diseases (potentially lethal tapeworms!!) which are infecting the Coyotes and the implications that has for co-habiting human populations. Studies Sage mentioned in the interview: E. multilocularis is especially prevalent in Edmonton/ Alberta: "Helminth parasites and zoonotic risk associated with urban coyotes (Canis latrans) in Alberta, Canada."; https://pubmed.ncbi.nlm.nih.gov/30588908/ Example of news article about this parasite in Alberta: https://www.cbc.ca/news/canada/calgary/tapeworm-echinococcus-multilocularis-alberta-klein-calgary-veterinarian-disease-coyotes-dogs-1.5224864 Example of the coyote downward spiral where bad food bad health bad behaviour: "Greater consumption of protein-poor anthropogenic food by urban relative to rural coyotes increases diet breadth and potential for human-wildlife conflict" ; https://onlinelibrary.wiley.com/doi/epdf/10.1111/ecog.01128 Coyotes that eat anthropogenic food have different microbiomes: "An altered microbiome in urban coyotes mediates relationships between anthropogenic diet and poor health" Example of Echinococcosis through a One Health Lens: "Neglected Zoonoses and the Missing Opportunities for One Health Education: The Case of Cystic Echinococcosis among Surgically Operated Patients in Basrah, Southern Iraq" A great, great paper showing that physicians are on top of their stuff!: Epidemiological and Clinical Characteristics of Alveolar Echinococcosis: An Emerging Infectious Disease in Alberta, Canada

On this episode of “Beyond the White Coat,” Rosha McCoy, MD, AAMC senior director for advancing clinical leadership and quality, talks with health care providers and experts to debunk common myths and share accurate information about the COVID-19 vaccines as part of the nation’s efforts to increase vaccinations and end the pandemic.Episode GuestsEaric Bonner, MD, is an internal medicine physician at Vidant Internal Medicine in Edenton, North Carolina. He also works at Vidant Chowan Hospital as a hospitalist and at the Brody School of Medicine at East Carolina University as an assistant professor of internal medicine. Currently, he serves as the medical director for ambulatory quality and patient safety; the regional medical director for the Vidant practices in Bertie, Chowan, and Perquimans counties; and director of continuing medical education for Vidant Chowan Hospital. He was formerly the hospitalist medical director and chief of medicine for Vidant Chowan Hospital. In his practice, he continues to teach students and residents from North Carolina’s medical, nursing, and physician assistant schools.Mamie Williams, MPH, is the director of nurse safety and well-being at Vanderbilt University Medical Center. She is currently completing a PhD in nursing from the University of Kansas. At present, she serves as the co-chair of the VUMC African American Employee Resource Group and the VUMC Racial Equity Task Force. Ms. Williams is also an advisory board member for the American Nurses Association’s Healthy Nurse, Healthy Nation national initiative. In her spare time, Ms. Williams is an avid gardener.  Ross McKinney Jr., MD, is the AAMC’s chief scientific officer, an infectious disease specialist, and a member of the Duke University faculty for over 30 years. During his time at Duke, he was director of the Division of Pediatric Infectious Diseases, vice dean for research at Duke University School of Medicine, and director of the Trent Center for Bioethics, Humanities, and History of Medicine. Dr. McKinney leads the AAMC’s programs that support medical research and the training of physician-scientists in academic medicine.Zanthia Wiley, MD, is the director of antimicrobial stewardship at Emory University Hospital Midtown. She completed medical school at the University of Alabama School of Medicine and both her Internal Medicine residency and Infectious Diseases fellowship at Emory. She has the unique experience of having worked as an academic hospitalist at Emory for 10 years prior to pursuing a career in infectious diseases. Dr. Wiley is dedicated to education and received the Jonas A. Shulman Teacher of the Year Award for 2018-2019, which is awarded yearly by the Emory Infectious Diseases fellows to a faculty member for excellence in teaching. She is a member of the Society for Healthcare Epidemiology of America Education Committee and the Infectious Diseases Society of America Medical Education Community of Practice. Dr. Wiley is the joint principal investigator on an institutional Woodruff Health Sciences Center COVID-19 Center for Urgent Research Engagement Award assessing “Clinical Characteristics, Outcomes, and Predictors of Readmission in Hospitalized COVID-19 Patients at Eight Atlanta Hospitals.” She is an investigator in several clinical trials, including the large national Adaptive COVID-19 Treatment Trial studies, and she is a co-investigator in the Emory Vaccine and Treatment Evaluation Unit. Dr. Wiley is a member of the Diversity, Equity, and Inclusion Council in Emory University School of Medicine's Department of Medicine and the Emory Collaborative Community Outreach and Health Disparities Research Initiative, and she serves as the physician lead of the Emory Healthcare COVID-19 Treatment Guidance Committee. She has given numerous talks on COVID-19 disparities on a local, regional, and national level and is dedicated to educating patients, their families, health care providers, and the community on the importance of COVID-19 vaccination.Credits:Hosted by Rosha McCoy, MD, AAMC senior director for advancing clinical leadership and quality.Produced by Stephanie Weiner, AAMC director of digital strategy and engagement.Recorded and edited by Laura Zelaya, AAMC production manager.With special contributions from Michelle Zajac, AAMC digital copy editor; Sholape Oriola, AAMC video specialist; John Buarotti, AAMC senior media relations specialist; and Mikhaila Richards, AAMC senior digital content strategist.You Might Also Be Interested In:“Convincing Rural Residents to Get a COVID-19 Vaccine” AAMCNews, April 15, 2021 More episodes in the “VaccineVoices” podcast seriesAAMC resources for media covering COVID-19 vaccination efforts Myths and facts about COVID-19 vaccines (CDC) 

With 200 million Americans having already received their COVID-19 vaccination, public health officials are warning that vaccine hesitancy is a growing challenge to our nation's ability to fully bounce back from the pandemic and resume something resembling the life we once knew.  If what you're seeing and hearing about the COVID vaccines on social media or from well-meaning friends and family is making you nervous, my guest, Dr. Dorlan Kimbrough, is joining me to set the record straight. Dr. Kimbrough is a member of the National MS Society's COVID Vaccine Guidance Task Force and we're talking about vaccine side effects among people living with MS, vaccine interactions with MS disease-modifying therapies, and other information that you should know before you go for your vaccination. We're also talking about new progressive MS research that's about to be funded by the International Progressive MS Alliance. We're sharing the good news about a DMT that's just been approved for people living with relapsing-remitting MS in England and Wales. And we'll share some of the research that was discussed last week at the American Academy of Neurology 2021 Annual Meeting. We have a lot to talk about! Are you ready for RealTalk MS??! International Progressive MS Alliance reviews research award applications  2:50    Kesimpta approved for RRMS in England and Wales  3:38 News from the AAN 2021 Annual Meeting    4:32 Dr. Dorlan Kimbrough discusses what you need to know about COVID-19 vaccines and MS  10:36 Share this episode  30:02 Have a minute? Leave a rating & review for the podcast  30:22 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email:  https://realtalkms.com/191 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS STUDY: Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels are Prognostic of Disability Worsening: A Biosignature that Helps Differentiating Active from Non-Active SPMS STUDY: Sociodemographic and Clinical Characteristics of Patients with Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry) Join the RealTalk MS Facebook Group Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating and Review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 191 Guests: Dr. Dorlan Kimbrough Tags: MS, MultipleSclerosis, COVID19, COVIDVaccine, MSResearch, MSSociety, RealTalkMS Privacy Policy

David O. Meltzer, MD, PhD, joins JAMA Network Open Digital Media Editor, Seth Trueger, MD, MPH, to discuss a cohort study examining whether patients' most recent vitamin D levels and treatment for insufficient vitamin D levels are associated with test results for coronavirus disease 2019 (COVID-19). Read the article here: https://ja.ma/2ZkvGpf. JNO Live is a weekly broadcast featuring conversations about the latest research being published in JAMA Network Open. Follow us on Facebook, Twitter and YouTube for details on the next broadcast.

In this episode, Dr. Grady and Garrett attempt to clear up the question, "what does it mean to be "immune compromised"? As diabetics we are often told that we are immune compromised or immune deficient, but is it that simple? Simply diabetic, does automatically mean we are immune compromised? We address these questions and attempt to provide a more complete picture of the immune system in relation to fighting off disease, and the many body systems that work with your immune system to get the job done. They also talk about various factors that can suppress the immune system and its ability to fight infections. Table of Contents: 3:07 - What is immunocompromised/immune deficient? 6:35 - CBC w/ diff break down 12:40 - Lymphatic system and the immune system 22:25 - What does immune compromised mean for diabetics? 26:35 - Diabetics' general infection and complication risk 30:00 - How the immune system of a diabetic is different 35:00 - The type of infection that diabetics are at greater risk for 36:20 - High blood sugar while you are sick 39:00 - Lymphocytopenia with COVID-19 and diabetes 41:44 - Do you need to have additional fear as a diabetic specifically? 45:10 - Co-morbidities and considerations for overall health 57:03 - Cardiovascular system, hypertension and Sars-CoV-2   PLEASE SUBSCRIBE TO THE PODCAST For more Diabuddies content follow us on The Diabuddies Podcast Facebook page. Twitter: @TheDiabuddies Instagram: @thediabuddiespodcast You can email us at TheDiabuddiesPodcast@gmail.com   Resources/Links Discussed in the episode: Holt, R.I.G., Cockram, C.S., Flyvbjerg, A., Goldstein, B.J., (2017). Chapter 55, p799, Diabetes and Infections. Textbook of Diabetes, Fifth Edition. Wiley Blackwell publishing. Knipe, H., & Bell, DJ., (April 2020). COVID-19. Radiopedia. https://radiopaedia.org/articles/covid-19-3?lang=us Hawryluk, M., (April 6 2020). Mysterious Heart Damage, Not Lung Troubles, Befalling COVID-19 Patients. Kaiser Health News. https://khn.org/news/mysterious-heart-damage-not-just-lung-troubles-befalling-covid-19-patients/ (March 2020). Here's the Damage Coronavirus (COVID-19) Can do to Your Lungs. Cleveland Clinic, Health Essentials. https://health.clevelandclinic.org/heres-the-damage-coronavirus-covid-19-can-do-to-your-lungs/ Life with T1D, (March 24, 2020). Your Coronavirus Questions Answered. JDRF. https://www.jdrf.org/blog/2020/03/24/answering-your-questions-coronavirus/ Wang, D., Hu, B., Hu, C., et al., (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus Infected Pneumonia in Wuhan, Chian. JAMA; 323(11): 1061-1069. https://jamanetwork.com/journals/jama/fullarticle/2761044 Patel, PS., Buras, ED., & Balasubramanyam, A., (2013). The Role of the Immune System in Obesity and Insulin Resistance. Journal of Obesity; 616193:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618935/

Estudo do eixo imunológico pulmonar-intestinal, importância dos receptores da enzima conversora de angiotensina e quadro clínico gastrointestinal.Referências Bibliográficas:1- He Y, Wen Q, Yao F et al. Gut-Lung Axis: The Microbial Contributions and Clinical Implications. Crit Rev Microbiol. 2017 Feb;43(1):81-95.2- Chan MC, Lee N, Chan PK et al. Fecal Detection of Influenza A Virus in Patients with Concurrent Respiratory and Gastrointestinal Symptoms. J Clin Virol. 2009 Jul; 45(3): 208-113- Gao QY, Chen YX, Fang JY. 2019 Novel Coronavirus Infection and Gastrointestinal Tract. J Dig Dis. 2020 Feb 254- Hamming I, Timens W, Bulthuis MLC et al. Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis. J Pathol 2004; 203: 631-637.5- Pan L, Mu M, Ren HG et al. Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: a Descriptive, Cross-sectional, Multicenter Study. 6- Ungaro RC, Sullivan T, Colombel J et al. What Should Gastroenterologists and Patients Know about COVID-19? Clin Gastroenterol Hepatol. 2020 Mar 17. pii: S1542- 3565(20)30330-X.

Episode Overview Review of COVID and SARS-CoV-2 including how it differs from the common cold and flu. Clinical characteristics Caution regarding treatments Background on testing Discussion on CCEMS specific responses. Question & Answers Links mentioned in this episode: NEJM paper “Clinical Characteristics of Coronavirus Disease 2019 in China” https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=TOC “Everything You Need to Know About Coronavirus Testing” https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-testing/ Two articles on why curing this virus is so hard and what treatments and vaccines look promising: https://www.vox.com/2020/3/11/21163262/is-there-a-cure-for-coronavirus https://www.statnews.com/2020/03/19/an-updated-guide-to-the-coronavirus-drugs-and-vaccines-in-development/ Use this link to ask questions that may be answered on our next podcast! https://bit.ly/2wooWLJ

Recorded March 19, 2020. With the games and lies we endured over the last two years. I am re-sharing to guarantee none of us forget what they've done.Current episodes: https://walkinverse.buzzsprout.com/In this episode #4, "Coronavirus (Covid-19) Don't Panic," we discuss pandemics with numbers to contrast and compare between H1N1 and now.  It doesn't minimize what the world is going through, but it shows how the media is purposely driving fear and panic to unprecedented levels.  They should be held accountable and pay for the lives they're destroying.Sources* “Autism Facts and Statistics.” April 17, 2019.* “2009 H1N1 Pandemic.” Centers for Disease Control and Prevention, June 11, 2019* “Preliminary In-Season 2019–2020 Flu Burden Estimates.” Centers for Disease Control and Prevention, March 13, 2020.* “Weekly U.S. Influenza Surveillance Report (FluView).” Centers for Disease Control and Prevention, March 13, 2020.* “CDC Novel H1N1 Flu,” January 16, 2010.* “Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study.” The Lancet 395, no. 10223 (February 15, 2020).* “Coronavirus Panic: What the Media Is Not Telling You Even If COVID-19 Mortality Rate Is 3.4%,” March 12, 2020.* “Autism Statistics: 1 in 88 U.S. Kids Affected, CDC Says.” March 29, 2012.* “MIT Biologist Says Fear Mongering on Coronavirus Will Go down as Biggest Fraud to Manipulate Economies,” March 12, 2020.* “How Does the New Coronavirus Compare with the Flu?” March 8, 2020.* “Flu Now Widespread in 45 States, What to Know.” Healthline, January 10, 2020.* “Flu Deaths Now Total 20,000, Including 136 Children.” Breitbart, March 7, 2020.* H1N1 Flu in Review: The HHS Response. Accessed March 18, 2020.* “Weekly National Flu Reports: 2018 to 2019 Season.” Accessed March 18, 2020.* “Influenza Update — 362.” World Health Organization, March 2, 2020.* “Real Time World Statistics.” Accessed March 18, 2020.WIV Reports — Uncensored is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit walkinverse.substack.com/subscribe

This episode #4, "Coronavirus (Covid-19) Don't Panic," talks about pandemics with numbers to contrast and compare between H1N1 and now.  It does not minimize what the world is going through, but it shows how the media is purposely driving fear and panic to unprecedented levels.  They should be held accountable and pay for the lives they are destroying. I will read a poem titled, "Party Lines" from my book Firestorm.To keep up to date of visiting me on the web to https://linktr.ee/walkinverseThank you, and enjoy the episode.New BookFirestorm: When History is Erasedhttps://www.amazon.com/dp/B084VQ48Q5Sources“Autism Facts and Statistics.”  April 17, 2019.“2009 H1N1 Pandemic.” Centers for Disease Control and Prevention, June 11, 2019“Preliminary In-Season 2019-2020 Flu Burden Estimates.” Centers for Disease Control and Prevention, March 13, 2020.“Weekly U.S. Influenza Surveillance Report (FluView).” Centers for Disease Control and Prevention, March 13, 2020.“CDC Novel H1N1 Flu,” January 16, 2010.“Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study.” The Lancet 395, no. 10223 (February 15, 2020).“Coronavirus Panic: What the Media Is Not Telling You Even If COVID-19 Mortality Rate Is 3.4%,” March 12, 2020.“Autism Statistics: 1 in 88 U.S. Kids Affected, CDC Says.” March 29, 2012.“MIT Biologist Says Fear Mongering on Coronavirus Will Go down as Biggest Fraud to Manipulate Economies,” March 12, 2020.“How Does the New Coronavirus Compare with the Flu?” March 8, 2020.“Flu Now Widespread in 45 States, What to Know.” Healthline, January 10, 2020.“Flu Deaths Now Total 20,000, Including 136 Children.” Breitbart, March 7, 2020.H1N1 Flu in Review: The HHS Response. Accessed March 18, 2020.“Weekly National Flu Reports: 2018 to 2019 Season.” Accessed March 18, 2020.“Influenza Update - 362.” World Health Organization, March 2, 2020.“Real Time World Statistics.” Accessed March 18, 2020.Support the show (https://walkinverse.com/support-walk-in-verse/)

Marie Spångberg ble Norges første kvinnelige lege i 1893, og med det banet hun og en håndfull andre vei for kvinner i medisin. Nå er 70 % av norske medisinstudenter kvinner. Vi snakker med lege og forfatter Cecilie Arentz-Hansen om stien de første kvinnene tråkket opp da – og hvor vi er nå. Cecilie Arentz-Hansen har skrevet om de 19 første norske kvinnelige legene i boken «Kvinder med Begavelse for Lægevirksomhed». Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no. Stetoskopet produseres av Irene Rønold og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.  Lydtekniker: Håkon Braaten / Moderne media  Coverillustrasjon: Stephen Lee Redaktøren snakker om disse artiklene:  - Clinical Characteristics of Coronavirus Disease 2019 in China- Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing- Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient- Indian pharma threatened by COVID-19 shutdowns in China- Is it time to nationalise the pharmaceutical industry?- Open peer-review platform for COVID-19 preprints- The altmetrics of Coronavirus – How research has shaped our understanding- Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?- In praise of replication studies and null results- Evidence Still Lacking for Recommendation of Screening for Cognitive Impairment in Older Adults- Egg consumption and risk of cardiovascular disease: three large prospective US cohort studies, systematic review, and updated meta-analysis- Egg consumption and cardiovascular disease

Vi snakker med Solveig Hofvind, leder for Mammografiprogrammet, om risikoen for å få påvist brystkreft blant kvinner med og uten kosmetiske brystimplantater. Les originalartikkelen i Tidsskriftet nr. 3/20, eller på nett: https://tidsskriftet.no/2020/02/originalartikkel/kosmetiske-brystimplantater-og-brystkreft. Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no. Stetoskopet produseres av Irene Rønold og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean. Lydtekniker: Håkon Braaten / Moderne media Coverillustrasjon: Stephen Lee Redaktøren snakker om disse artiklene: - Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China - Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China - Presumed Asymptomatic Carrier Transmission of COVID-19 - More than 80 clinical trials launch to test coronavirus treatments - Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China - As coronavirus spreads, the time to think about the next epidemic is now - Popular preprint servers face closure because of money troubles - Milk and Health - Association of coincident self-reported mental health problems and alcohol intake with all-cause and cardiovascular disease mortality: A Norwegian pooled population analysis

I denne episoden snakker vi med Kari Schrøder Hansen. Hun er spesialist i generell kirurgi og har blant annet vært på oppdrag verdens største flyktningleir i Bangladesh og i al-Hol-leiren i Syria. Vi får høre litt om hva hun har opplevd og kontrasten det er i å jobbe som lege ute i felt og å komme hjem til Norge etterpå.Les artikkelen om feltarbeid i Bangladesh her: https://tidsskriftet.no/2018/06/aktuelt-i-foreningen/store-helseutfordringer-i-verdens-storste-flyktningleirTilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no.Stetoskopet produseres av Irene Rønold og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.Lydtekniker: Håkon Braaten / Moderne media Coverillustrasjon: Stephen LeeArtikler nevnt i Redaktørens hjørne:Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaRemdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroFirst Case of 2019 Novel Coronavirus in the United States2019 Novel Coronavirus—Important Information for CliniciansCoronavirus Infections—More Than Just the Common ColdNovel Coronavirus (2019-nCoV) situation reportsEpidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyEpidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, ChinaAnother Decade, Another CoronavirusAbraar Karan: Coronavirus—containing the parallel epidemics of xenophobia and misinformationAssociation between financial links to indoor tanning industry and conclusions of published studies on indoor tanning: systematic reviewAssisted dying: Belgian doctors are acquitted of unlawful poisoningLooking beyond BrexitGlobal genomics project unravels cancer's complexity at unprecedented scaleOrgan Donation after Medical Assistance in Dying — Canada's First Cases